Document:

exv10w7

 

Exhibit 10.7

VOTING AGREEMENT

          VOTING AGREEMENT, dated as of March ___, 2006 (this “Agreement”), by and among Touchstone
Resources USA, Inc., a Delaware corporation (the “Company”), and the stockholders listed on the
signature pages hereto under the heading “Stockholders” (each a “Stockholder” and collectively, the
“Stockholders”).

          WHEREAS, the Company and certain investors (each, an “Investor”, and collectively, the
“Investors”) have entered into a Securities Purchase Agreement, dated as of the date hereof (the
“Securities Purchase Agreement”), pursuant to which, among other things, the Company has agreed to
issue and sell to the Investors and the Investors have agreed to purchase, (i) convertible notes of
the Company which will, among other things, be convertible into shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”) and (ii) two series of warrants to acquire
shares of Common Stock.

          WHEREAS, as of the date hereof, the Stockholders own collectively ___shares of Common
Stock, which represent in the aggregate approximately ___% of the total issued and outstanding
capital stock of the Company; and

          WHEREAS, as a condition to the willingness of the Investors to enter into the Securities
Purchase Agreement and to consummate the transactions contemplated thereby (collectively, the
“Transaction”), the Investors have required that each Stockholder agree, and in order to induce the
Investors to enter into the Securities Purchase Agreement, each Stockholder has agreed, to enter
into this Agreement with respect to all the Common Stock now owned and which may hereafter be
acquired by the Stockholder and any other securities, if any, which such Stockholder is currently
entitled to vote, or after the date hereof, becomes entitled to vote, at any meeting of
stockholders of the Company (the “Other Securities”).

          NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as
follows:

ARTICLE I

VOTING AGREEMENT OF THE STOCKHOLDER

          SECTION 1.01. Voting Agreement. Subject to the last sentence of this Section 1.01,
each Stockholder hereby agrees that at any meeting of the stockholders of the Company, however
called, and in any action by written consent of the Company’s stockholders, each of the
Stockholders shall vote the Common Stock and the Other Securities: (a) in favor of the Stockholder
Approval (as defined in the Securities Purchase Agreement), including the Capital Increase (as
defined in the Securities Purchase Agreement), as described in Section 4(q) of the Securities
Purchase Agreement; and (b) against any proposal or any other corporate action or agreement that
would result in a breach of any covenant, representation or warranty or any other obligation or
agreement of the Company under the Securities Purchase Agreement or which could result in any of
the conditions to the Company’s obligations under the Securities Purchase Agreement not being
fulfilled. Each Stockholder acknowledges receipt and review of a copy of the Securities Purchase
Agreement and the other Transaction Documents (as defined in

 

 

the Securities Purchase Agreement). The obligations of the Stockholders under this Section
1.01 shall terminate immediately following the occurrence of the Stockholder Approval.

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER

          Each Stockholder hereby represents and warrants, severally but not jointly, to each of the
Investors as follows:

          SECTION 2.01. Authority Relative to This Agreement. Each Stockholder has all
necessary power and authority to execute and deliver this Agreement, to perform his or its
obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has
been duly executed and delivered by such Stockholder and constitutes a legal, valid and binding
obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms,
except (a) as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or similar laws now or hereafter in effect
relating to, or affecting generally the enforcement of creditors’ and other obligees’ rights, (b)
where the remedy of specific performance or other forms of equitable relief may be subject to
certain equitable defenses and principles and to the discretion of the court before which the
proceeding may be brought, and (c) where rights to indemnity and contribution thereunder may be
limited by applicable law and public policy.

          SECTION 2.02. No Conflict. (a) The execution and delivery of this Agreement by such
Stockholder does not, and the performance of this Agreement by such Stockholder shall not, (i)
conflict with or violate any federal, state or local law, statute, ordinance, rule, regulation,
order, judgment or decree applicable to any Stockholder or by which the Common Stock or the Other
Securities owned by such Stockholder are bound or affected or (ii) result in any breach of or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, or
result in the creation of a lien or encumbrance on any of the Common Stock or the Other Securities
owned by such Stockholder pursuant to, any note, bond, mortgage, indenture, contract, agreement,
lease, license, permit, franchise or other instrument or obligation to which such Stockholder is a
party or by which such Stockholder or the Common Stock, Class B Common Stock or Other Securities
owned by such Stockholder are bound.

          (b) The execution and delivery of this Agreement by such Stockholder does not, and the
performance of this Agreement by such Stockholder shall not, require any consent, approval,
authorization or permit of, or filing with or notification to, any governmental entity by such
Stockholder.

          SECTION 2.03. Title to the Stock. As of the date hereof, each Stockholder is the
owner of the number of shares of Common Stock set forth opposite its name on Appendix A
attached hereto, entitled to vote, without restriction, on all matters brought before holders of
capital stock of the Company, which Common Stock represent on the date hereof the percentage of the
outstanding stock and voting power of the Company set forth on such Appendix. Such Common Stock
are all the securities of the Company owned, either of record or beneficially, by such Stockholder.
Such Common Stock are owned free and clear of all security interests, liens, claims, pledges,
options, rights of first refusal, agreements, limitations on such Stockholder’s

2

 

voting rights, charges and other encumbrances of any nature whatsoever. No Stockholder has
appointed or granted any proxy, which appointment or grant is still effective, with respect to the
Common Stock or Other Securities owned by such Stockholder.

ARTICLE III

COVENANTS

          SECTION 3.01. No Disposition or Encumbrance of Stock. Each Stockholder hereby
covenants and agrees that, until Stockholder Approval, except as contemplated by this Agreement,
such Stockholder shall not offer or agree to sell, transfer, tender, assign, hypothecate or
otherwise dispose of, grant a proxy or power of attorney with respect to, or create or permit to
exist any security interest, lien, claim, pledge, option, right of first refusal, agreement,
limitation on such Stockholder’s voting rights, charge or other encumbrance of any nature
whatsoever (“Encumbrance”) with respect to the Common Stock or Other Securities, directly or
indirectly, initiate, solicit or encourage any person to take actions which could reasonably be
expected to lead to the occurrence of any of the foregoing; provided, however, that
any such Stockholder may assign, sell or transfer any Common Stock or Other Securities provided
that any such recipient of the Common Stock or Other Securities has delivered to the Company and
each Investor a written agreement in a form reasonably satisfactory to the Investors that the
recipient shall be bound by, and the Common Stock and/or Other Securities so transferred, assigned
or sold shall remain subject to this Agreement.

          SECTION 3.02. Company Cooperation. The Company hereby covenants and agrees that it
will not, and each Stockholder irrevocably and unconditionally acknowledges and agrees that the
Company will not (and waives any rights against the Company in relation thereto), recognize any
Encumbrance or agreement on any of the Common Stock or Other Securities subject to this Agreement
unless the provisions of Section 3.01 have been complied with. The Company agrees to use its
reasonable best efforts to ensure that at any time in which any Stockholder Approval is required
pursuant to Section 4(q) of the Securities Purchase Agreement, it will cause holders of Common
Stock or Other Securities representing the percentage of outstanding capital stock required to vote
in favor of the Transaction in order for the Company to comply with its obligations under Section
4(q) of the Securities Purchase Agreement to become party to and bound by the terms and conditions
of this Agreement and the Common Stock and Other Securities held by such holders to be subject to
the terms and conditions of this Agreement.

ARTICLE IV

MISCELLANEOUS

          SECTION 4.01. Further Assurances. Each Stockholder will execute and deliver such
further documents and instruments and take all further action as may be reasonably necessary in
order to consummate the transactions contemplated hereby.

          SECTION 4.02. Specific Performance. The parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement was not performed in accordance with the
terms hereof and that any Investor (without being joined by any other Investor) shall be entitled
to specific performance of the terms hereof, in addition to any other

3

 

remedy at law or in equity. Any Investor shall be entitled to its reasonable attorneys’ fees
in any action brought to enforce this Agreement in which it is the prevailing party.

          SECTION 4.03. Entire Agreement. This Agreement constitutes the entire agreement among
the Company and the Stockholders (other than the Securities Purchase Agreement and the other
Transaction Documents) with respect to the subject matter hereof and supersedes all prior
agreements and understandings, both written and oral, among the Company and the Stockholders with
respect to the subject matter hereof.

          SECTION 4.04. Amendment. This Agreement may not be amended except by an instrument in
writing signed by the parties hereto.

          SECTION 4.05. Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other
conditions and provisions of this Agreement shall nevertheless remain in full force and effect so
long as the economic or legal substance of this Agreement is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the terms of this Agreement remain as originally contemplated to
the fullest extent possible.

          SECTION 4.06. Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by the internal laws of the
State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of
the laws of any jurisdictions other than the State of New York. The parties hereby agree that all
actions or proceedings arising directly or indirectly from or in connection with this Agreement
shall be litigated only in the Supreme Court of the State of New York or the United States District
Court for the Southern District of New York located in New York County, New York. The parties
consent to the jurisdiction and venue of the foregoing courts and consent that any process or
notice of motion or other application to any of said courts or a judge thereof may be served inside
or outside the State of New York or the Southern District of New York by registered mail, return
receipt requested, directed to the party being served at its address set forth on the signature
ages to this Agreement (and service so made shall be deemed complete three (3) days after the same
has been posted as aforesaid) or by personal service or in such other manner as may be permissible
under the rules of said courts. Each of the Company and each Stockholder irrevocably waives, to
the fullest extent permitted by law, any objection which it may now or hereafter have to the laying
of the venue of any such suit, action, or proceeding brought in such a court and any claim that
suit, action, or proceeding has been brought in an inconvenient forum. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY
TRANSACTION CONTEMPLATED HEREBY.

          SECTION 4.07. Third-Party Beneficiaries. The Investors shall be intended third party
beneficiaries of this Agreement to the same extent as if they were parties hereto, and shall be
entitled to enforce the provisions hereof.

4

 

          SECTION 4.08. Termination. This Agreement shall terminate immediately following the
occurrence of the Stockholder Approval or upon the mutual consent of each Stockholder and the
Investors.

[Signature Page Follows]

5

 

     IN WITNESS WHEREOF, each Stockholder and the Company has duly executed this
Agreement.

	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	THE COMPANY:	 	 
	 
	 	 	 	 	 	 
	 	 	TOUCHSTONE RESOURCES USA, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	      Name:	 	 
	 

	 	 	 	      Title:	 	 
	 
	 	 	 	 	 	 
	Dated: March___, 2006
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Address
	 	: 1600 Smith Street,	 	 
	 

	 	 	 	Houston, TX 77002	 	 

 

 

	 	 	 	 	 
	 

	 	 	 	 
	 

	 	STOCKHOLDER:	 	 
	 

	 	ROGER ABEL	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Dated: March ___, 2006
	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 

 

 

	 	 	 	 	 
	 

	 	STOCKHOLDER:	 	 
	 

	 	STEPHEN P. HARRINGTON	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Dated: March ___, 2006
	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 

 

 

	 	 	 	 	 
	 

	 	STOCKHOLDER:	 	 
	 

	 	STEPHEN C. HAYNES	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Dated: March ___, 2006
	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 

 

 

	 	 	 	 	 
	 

	 	STOCKHOLDER:	 	 
	 

	 	[OTHER STOCKHOLDERS]	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Dated: March ___, 2006
	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 

 

 

APPENDIX A

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Voting Percentage	 
	 	 	Common Stock	 	 	Percentage of Stock	 	 	of Stock	 
	Stockholder	 	Owned	 	 	Outstanding	 	 	Outstanding	 
	Roger Abel
	 	 	 	 	 	 	 	 	 	 	 	 
	Stephen P. Harrington
	 	 	 	 	 	 	 	 	 	 	 	 
	Stephen C. Haynes
	 	 	 	 	 	 	 	 	 	 	 	 
	[OTHER STOCKHOLDERS]exv10w1

 

Exhibit 10.1

RELÌV INTERNATIONAL, INC.

2,300,000 Shares*

Common Stock

($0.001 par value per share)

 

Underwriting Agreement

April 5, 2006

Canaccord Adams Inc.

Avondale Partners, LLC

The Seidler Companies Incorporated

as Representatives of the several

Underwriters named in Schedule I hereto

c/o Canaccord Adams Inc.

99 High Street, 11th Floor

Boston, Massachusetts 02110

     Dear Sirs:

     Relìv International, Inc., a Delaware corporation (the “Company”), proposes, subject to the
terms and conditions stated herein, to issue and sell to the several underwriters named in
Schedule I hereto (collectively, the “Underwriters”) an aggregate of 2,300,000 shares of
common stock, par value $0.001 per share, of the Company (“Common Stock”), and the stockholders of
the Company named in Schedule II hereto (the “Selling Stockholders”) propose, subject to
the terms and conditions stated herein, to sell to the Underwriters an aggregate of 2,000,000
shares and, at the election of the Underwriters, up to 300,000 additional shares of Common Stock
(as and to the extent indicated in Schedule II hereto). The aggregate of 2,000,000 shares
to be sold by the Company and the Selling Stockholders is herein called the “Firm Shares” and the
aggregate of 300,000 additional shares to be sold by certain of the Selling Stockholders is herein
called the “Optional Shares.” The Firm Shares and the Optional Shares which the Underwriters elect
to purchase pursuant to Section 3 hereof are herein collectively called the “Shares.”

     1. Representations and Warranties.

          (a) Representations and Warranties of the Company. The Company represents and
warrants to, and agrees with, each of the Underwriters that:

               (i) A registration statement on Form S-3 (File No. 333-131974) (the “Initial Registration
Statement”) in respect of the Shares has been filed with the Securities and Exchange Commission
(the “Commission”); the Initial Registration Statement including any pre-effective amendments
thereto and any post-effective amendments thereto, each in the form heretofore delivered to
Canaccord Adams Inc. and, excluding exhibits thereto, but including all documents incorporated by
reference in the prospectus contained therein, delivered to Canaccord

 

			
	*	 	Includes 300,000 shares subject to an option
to purchase additional shares to cover over-allotments.

 

 

Adams Inc. for each of the other Underwriters, have been declared effective by the Commission
in such form; other than a registration statement, if any, increasing the size of the offering (a
“Rule 462(b) Registration Statement”), filed pursuant to Rule 462(b) under the Securities Act of
1933, as amended (the “Act”), which became effective upon filing, no other document with respect to
the Initial Registration Statement or document incorporated by reference therein has heretofore
been filed with the Commission; and no stop order suspending the effectiveness of the Initial
Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration
Statement, if any, has been issued and no proceeding for that purpose has been initiated or, to the
Company’s knowledge, threatened by the Commission (any preliminary prospectus included in the
Initial Registration Statement or filed with the Commission pursuant to Rule 424(a) of the rules
and regulations of the Commission under the Act is hereinafter called a “Preliminary Prospectus”);
the various parts of the Initial Registration Statement and the Rule 462(b) Registration Statement,
if any, including all exhibits to the foregoing (including any exhibits incorporated by reference)
and (i) including the information contained in the form of final prospectus filed with the
Commission pursuant to Rule 424(b) under the Act in accordance with Section 5(a) hereof or the Rule
462(b) Registration Statement, if any, at the time it became effective and (ii) the documents
incorporated by reference in the prospectus contained in the Initial Registration Statement at the
time such part of the Initial Registration Statement became effective, each as amended at the time
such part of such Initial Registration Statement became effective, are hereinafter collectively
called the “Registration Statement”; such final prospectus, in the form first filed pursuant to
Rule 424(b) under the Act, is hereinafter called the “Prospectus”; the term “Pricing Prospectus” as
used herein means the Preliminary Prospectus that was included in the Registration Statement
immediately prior to the Applicable Time (as defined in Section 1(a)(ii) hereof); any reference
herein to “Issuer Free Writing Prospectus” refers to any “issuer free writing prospectus” as
defined in Rule 433 under the Act; and any reference herein to any Preliminary Prospectus or the
Prospectus shall be deemed to refer to and include the documents incorporated by reference therein
pursuant to Item 12 of Form S-3 under the Act, as of the date of such Preliminary Prospectus or
Prospectus, as the case may be;

               (ii) For the purposes of this Agreement, the “Applicable Time” is 4:00 p.m. (Eastern Time) on
the date of this Agreement; the Pricing Prospectus as supplemented by the Issuer Free Writing
Prospectuses, if any, and other documents listed on Schedule III(a) hereto, taken together
(collectively, the “Pricing Disclosure Package”) as of the Applicable Time, did not include any
untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not
misleading; and each Issuer Free Writing Prospectus listed on Schedule III(a) or
Schedule III(b) hereto does not conflict with the information contained in the Registration
Statement, the Pricing Prospectus or the Prospectus and each Issuer Free Writing Prospectus listed
on Schedule III(b) hereto, as supplemented by and taken together with the Pricing
Disclosure Package as of the Applicable Time, did not include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided,
however, that this representation and warranty shall not apply to any statements or
omissions made in the Pricing Prospectus or an Issuer Free Writing Prospectus in reliance upon and
in conformity with information furnished in writing to the Company by an Underwriter through
Canaccord Adams Inc. expressly for use therein or by a Selling Stockholder expressly for use in the
preparation of the answers therein to Item 7 of Form S-3;

 

 

               (iii) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer
Free Writing Prospectus has been issued by the Commission, and each Preliminary Prospectus, at the
time of filing thereof, conformed in all material respects to the requirements of the Act and the
rules and regulations of the Commission thereunder, and did not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that this representation and warranty shall not
apply to any statements or omissions made in reliance upon and in conformity with information
furnished in writing to the Company by an Underwriter through Canaccord Adams Inc. expressly for
use therein or by a Selling Stockholder expressly for use in the preparation of the answers therein
to Item 7 of Form S-3;

               (iv) The documents incorporated by reference in any Preliminary Prospectus or the Prospectus,
when they became effective or were filed with the Commission, as the case may be, conformed in all
material respects to the requirements of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and the rules and regulations of the Commission thereunder, and none of such
documents contained an untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements therein not misleading;

               (v) The Registration Statement and all Preliminary Prospectuses conform, and the Prospectus
and any further amendments or supplements to the Registration Statement, any Preliminary Prospectus
or the Prospectus will conform, in all material respects to the requirements of the Act and the
rules and regulations of the Commission thereunder; the Registration Statement, any Preliminary
Prospectus and the Prospectus do not and will not, as of the applicable effective date as to the
Registration Statement and any amendment thereto, as of the applicable filing date as to any
Preliminary Prospectus, and as of the applicable filing date and the applicable Time of Delivery
(as hereinafter defined) as to the Prospectus and any amendment or supplement thereto, contain an
untrue statement of a material fact or omit to state a material fact, in the case of the
Registration Statement or any amendment thereto, required to be stated therein or necessary to make
the statements therein not misleading and, in the case of any Preliminary Prospectus or the
Prospectus or any supplement thereto, necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that
this representation and warranty shall not apply to any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by an Underwriter
through Canaccord Adams Inc. expressly for use therein or by a Selling Stockholder expressly for
use in the preparation of the answers therein to Item 7 of Form S-3;

               (vi) There are no contracts or other documents required to be described in the Registration
Statement or to be filed as exhibits to the Registration Statement by the Act or by the rules and
regulations thereunder which have not been described in, filed as exhibits to, or incorporated by
reference in the Registration Statement, as required; the contracts so described in the Pricing
Prospectus and the Prospectus to which the Company or any of its subsidiaries is a party have been
duly authorized, executed and delivered by the Company or its subsidiaries, constitute valid and
binding agreements of the Company or its subsidiaries and are enforceable against the Company or
its subsidiaries in accordance with their respective terms, except as such

 

 

enforceability may be limited by (i) applicable bankruptcy, insolvency, moratorium,
reorganization, fraudulent conveyance or similar laws in effect which affect the enforcement of
creditors’ rights generally, (ii) general principles of equity, whether considered in a proceeding
at law or in equity and (iii) state or federal securities laws or policies relating to the
non-enforceability of the indemnification provisions contained therein, and, to the Company’s
knowledge, such contracts are enforceable in accordance with their respective terms by the Company
against the other parties thereto, except as such enforceability may be limited by (x) applicable
bankruptcy, insolvency, moratorium, reorganization, fraudulent conveyance or similar laws in effect
which affect the enforcement of creditors’ rights generally, (y) general principles of equity,
whether considered in a proceeding at law or in equity and (z) state or federal securities laws or
policies relating to the non-enforceability of the indemnification provisions contained therein,
and such contracts are in full force and effect on the date hereof; and neither the Company nor any
of its subsidiaries, nor, to the best of the Company’s knowledge, any other party thereto, is in
breach of or default under any of such contracts, except for such breaches or defaults that will
not result in a material adverse change in the general affairs, business, assets, management,
financial position, stockholders’ equity or results of operations of the Company and its
subsidiaries taken as a whole;

               (vii) Neither the Company nor any of its subsidiaries has sustained since the date of the
latest audited financial statements included or incorporated by reference in the Pricing Prospectus
any loss or interference with its business from fire, explosion, flood or other calamity, whether
or not covered by insurance, or from any labor dispute or court or governmental action, order or
decree, that is in each case material to the Company and its subsidiaries taken as a whole,
otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective
dates as of which information is given in the Registration Statement and the Pricing Prospectus,
(i) there has not been any change in the capital stock or long-term debt of the Company or any of
its subsidiaries or any material adverse change or any development involving a prospective material
adverse change, in or affecting the general affairs, business, assets, management, financial
position, stockholders’ equity or results of operations of the Company and its subsidiaries taken
as a whole, and (ii) the Company or its subsidiaries have not entered into material transaction or
incurred any material obligation outside of the ordinary course of business, otherwise than as set
forth in the Pricing Prospectus;

               (viii) The Company and its subsidiaries have good and marketable title in fee simple to all
real property and good and marketable title to all other tangible properties and assets described
in the Pricing Prospectus as owned by it, in each case free and clear of all liens, charges,
claims, encumbrances or restrictions, except such as (i) are described in the Pricing Prospectus or
(ii) do not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries; any real property and
buildings held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the Company and its
subsidiaries; the Company and its subsidiaries own or lease all such properties as are necessary to
its operations as now conducted or as proposed to be conducted;

               (ix) Each of the Company and its subsidiaries has been duly incorporated and is validly
existing as a corporation in good standing under the laws of its

 

 

respective jurisdiction of organization, each with full power and authority (corporate and
otherwise) to own its properties and conduct its business as described in the Pricing Prospectus,
and each has been duly qualified as a foreign corporation for the transaction of business and is in
good standing under the laws of each other jurisdiction in which it owns or leases properties or
conducts any business so as to require such qualification, except where the failure to be so
qualified or in good standing would not result in any material liability or disability to the
Company or such subsidiary;

               (x) The Company has an authorized capitalization as set forth in the Pricing Prospectus and
the Prospectus, and all the issued shares of capital stock of the Company have been duly and
validly authorized and issued, are fully paid and non-assessable and conform to the descriptions
thereof contained or incorporated by reference in the Pricing Prospectus and the Prospectus; all of
the issued shares of capital stock of each subsidiary of the Company (i) have been duly and validly
authorized and issued, are fully paid and non-assessable and (ii) except as disclosed in the
Pricing Prospectus and the Prospectus, are owned directly by the Company, free and clear of all
liens, encumbrances, equities or claims; except as disclosed in or contemplated by the Pricing
Prospectus and the Prospectus and the consolidated financial statements of the Company, and the
related notes thereto, contained or incorporated by reference in the Pricing Prospectus and the
Prospectus, neither the Company nor any subsidiary has outstanding any options to purchase, or any
preemptive rights or other rights to subscribe for or to purchase any securities or obligations
convertible into, or any contracts or commitments to issue or sell, shares of its capital stock or
any such options, rights, convertible securities or obligations; and the description of the
Company’s stock option and stock purchase plans and the options or other rights granted and
exercised thereunder set forth in the Pricing Prospectus and the Prospectus accurately and fairly
presents the information required by the Act and the published rules and regulations of the
Commission thereunder to be shown with respect to such plans, options and rights;

               (xi) The unissued Shares to be issued and sold by the Company to the Underwriters hereunder
have been duly and validly authorized and, when issued and delivered against payment therefor as
provided herein, will be duly and validly issued and fully paid and non-assessable and will conform
to the description of the Common Stock contained or incorporated by reference in the Pricing
Prospectus and the Prospectus; no preemptive rights or other rights to subscribe for or purchase
exist with respect to the issuance and sale of the Shares by the Company pursuant to this
Agreement; no stockholder of the Company has any right, which has not been waived, to require the
Company to register the sale of any shares of capital stock owned by such stockholder under the Act
in the public offering contemplated by this Agreement; and no further approval or authority of the
stockholders or the Board of Directors of the Company will be required for the issuance and sale of
the Shares to be sold by the Company as contemplated herein;

               (xii) The Company has full corporate power and authority to enter into this Agreement; and
this Agreement has been duly authorized, executed and delivered by the Company, constitutes a valid
and binding obligation of the Company and is enforceable against the Company in accordance with its
terms;

 

 

               (xiii) The issue and sale of the Shares by the Company and the compliance by the Company with
all of the provisions of this Agreement and the consummation of the transactions herein
contemplated will not conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan
agreement or other material agreement or material instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the property or assets of the Company or any of its subsidiaries is subject, nor will any such
actions result in any violation of the provisions of the Certificate of Incorporation or By-laws of
the Company as currently in effect or any statute or any order, rule or regulation of any court or
governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any
of their properties; and no consent, approval, authorization, order, registration or qualification
of or with any such court or governmental agency or body is required for the issue and sale of the
Shares or the consummation by the Company of the transactions contemplated by this Agreement,
except the registration under the Act of the Shares and such consents, approvals, authorizations,
registrations or qualifications as may be required under state securities or Blue Sky laws or the
bylaws and rules of the National Association of Securities Dealers, Inc. (“NASD”) in connection
with the purchase and distribution of the Shares by the Underwriters;

               (xiv) Neither the Company nor any of its subsidiaries is in violation of its Certificate of
Incorporation or By-laws or in default in the performance or observance of any material obligation,
agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan
agreement, lease or other agreement or instrument to which it is a party or by which it or any of
its properties may be bound;

               (xv) The statements set forth in the Pricing Prospectus and the Prospectus under the caption
“Underwriting,” insofar as they purport to describe the provisions of the laws and documents
referred to therein, are accurate, complete and fair;

               (xvi) Except as disclosed in the Pricing Prospectus, there are no material legal or
governmental actions, suits or proceedings pending or, to the best of the Company’s knowledge,
threatened to which the Company or any of its subsidiaries is or may be a party or of which
property owned or leased by the Company or any of its subsidiaries is or may be the subject, or
related to environmental or discrimination matters; no labor disturbance by the employees of the
Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent; and
neither the Company nor any of its subsidiaries is a party or subject to the provisions of any
material injunction, judgment, decree or order of any court, regulatory body;

               (xvii) The Company and its subsidiaries possess all licenses, certificates, authorizations or
permits issued by the appropriate governmental or regulatory agencies or authorities that are
necessary to enable them to own, lease and operate their respective properties and to carry on
their respective businesses as presently conducted; and neither the Company nor any of its
subsidiaries has received any notice of proceedings relating to the revocation or modification of
any such license, certificate, authority or permit;

               (xviii) The Company and its subsidiaries (i) are in compliance in all material respects with
any and all applicable foreign, federal, state and local laws and regulations

 

 

relating to the protection of human health and safety, including, without limitation, those
relating to occupational safety and health, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants, including, without limitation, those relating to the storage,
handling or transportation of hazardous or toxic materials (collectively, “Environmental Laws”) and
(ii) are in compliance with all terms and conditions of any such permit, license or approval. The
Company, in its reasonable judgment, has concluded that any costs or liabilities associated with
Environmental Laws (including, without limitation, any capital or operating expenditures required
for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or
approval, any related constraints on operating activities and any potential liabilities to third
parties) would not, singly or in the aggregate, reasonably be expected to result in a material
adverse change in the general affairs, business, assets, management, financial position,
stockholders’ equity or results of operations of the Company and its subsidiaries taken as a whole;

               (xix) Ernst & Young LLP, who have audited certain financial statements of the Company, are
independent public accountants as required by the Act and the rules and regulations of the
Commission thereunder and have been appointed by an Audit Committee comprised entirely of
independent directors of the Board of Directors of the Company;

               (xx) The consolidated financial statements and schedules of the Company, and the related notes
thereto, included or incorporated by reference in the Registration Statement and the Pricing
Prospectus present fairly the financial position of the Company as of the respective dates of such
financial statements and schedules, and the results of operations and cash flows of the Company for
the respective periods covered thereby; such statements, schedules and related notes have been
prepared in accordance with generally accepted accounting principles in the United States applied
on a consistent basis as certified by the independent public accountants named in paragraph above;
no other financial statements or schedules are required to be included or incorporated by reference
in the Registration Statement; and the selected financial data set forth in the Pricing Prospectus
under the captions “Capitalization,” “Selected Consolidated Financial Data” and “Prospectus
Summary—Summary Consolidated Financial Data” fairly present the information set forth therein on
the basis stated in the Registration Statement;

               (xxi) The Company owns, or possesses and/or has been granted valid and enforceable licenses
for, all registered patents, patent applications, trademarks, trademark applications, tradenames,
servicemarks and copyrights necessary to the conduct of its business as such business is described
in the Pricing Prospectus (collectively, the “Registered Intellectual Property”). The Company has
no knowledge of any material infringement or misappropriation by third parties of (a) any of the
Registered Intellectual Property, or (b) any material inventions, manufacturing processes,
formulae, trade secrets, know-how, unregistered trademarks, and other intangible property and
assets necessary to the conduct of its business as such business is described in the Pricing
Prospectus (collectively, the “Other Intellectual Property,” and together with the Registered
Intellectual Property, the “Intellectual Property”), nor is there any pending or, to the best
knowledge of the Company, threatened material action, suit, proceeding or claim by others
challenging the Company’s rights of title or other interest in or to any Intellectual Property and
the Company does not know of any facts which would form a reasonable basis for any such claim.
There is no pending or, to the best knowledge of the

 

 

Company, threatened material action, suit, proceeding or claim by others challenging the
validity and scope of any Intellectual Property and the Company does not know of any facts which
would form a reasonable basis for any such claim. There is no pending or, to the best knowledge of
the Company, threatened material action, suit, proceeding or claim by others that the Company or
any of its products or processes or the Intellectual Property infringe or otherwise violate any
patent, trademark, servicemark, copyright, trade secret or other proprietary right of others and
the Company is unaware of any facts which would form a reasonable basis for any such claim. The
Company is not aware of (i) any grounds for an interference proceeding before the United States
Patent and Trademark Office in relation to any of the patents or patent applications currently
owned by the Company, or (ii) any facts which would bar the grant of a patent from each of the
patent applications described in the Pricing Prospectus. There is no pending or, to the best
knowledge of the Company, threatened action, suit proceeding or claim by any current or former
employee, consultant or agent of the Company seeking either ownership rights to any invention or
other intellectual property right or compensation from the Company for any invention or other
intellectual property right made by such employee, consultant or agent in the course of his/her
employment with the Company or otherwise. There is no act or omission by the Company or its agents
or representatives of which the Company has knowledge that may render any patent or patent
application within the Intellectual Property unpatentable, unenforceable or invalid. Each of the
Pricing Prospectus fairly and accurately describes in all material respects the Company’s rights
with respect to the Intellectual Property;

               (xxii) The Company and each of its subsidiaries have filed all necessary federal, state and
foreign income and franchise tax returns, each of which has been true and correct in all material
respects, and have paid all taxes shown as due thereon; and the Company has no knowledge of any
material tax deficiency which has been or might be asserted or threatened against the Company or
any of its subsidiaries;

               (xxiii) The Company is not an “investment company” or an “affiliated person” of, or “promoter”
or “principal underwriter” for, an “investment company”, as such terms are defined in the
Investment Company Act of 1940, as amended (the “Investment Company Act”);

               (xxiv) Each of the Company and its subsidiaries maintains insurance of the types and in the
amounts which it deems adequate for its business, including, but not limited to, insurance covering
real and personal property owned or leased by the Company and its subsidiaries against theft,
damage, destruction, acts of vandalism and all other risks customarily insured against, all of
which insurance is in full force and effect;

               (xxv) Neither the Company nor any of its subsidiaries has at any time during the last five
years (i) made any unlawful contribution to any candidate for foreign office, or failed to disclose
fully any contribution in violation of law, or (ii) made any payment to any foreign, federal or
state governmental officer or official, or other person charged with similar public or quasi-public
duties, other than payments required or permitted by the laws of the United States, any foreign
government or any respective jurisdiction thereof;

               (xxvi) The Company has not taken and will not take, directly or indirectly through any of its
directors, officers or controlling persons, any action which is designed to or

 

 

which has constituted or which might reasonably be expected to cause or result in
stabilization or manipulation of the price of any security of the Company to facilitate the sale or
resale of the Shares;

               (xxvii) The Common Stock of the Company has been registered pursuant to Section 12(g) of the
Exchange Act and the Company is not required to take any further action for the inclusion of the
Shares on the Nasdaq National Market;

               (xxviii) There are no business relationships or related-party transactions involving the
Company or any subsidiary or any other person required to be described in the Pricing Prospectus
which have not been described as required;

               (xxix) The Company maintains a system of internal control over financial reporting (as such
term is defined in Rule 13a-15(f) under the Exchange Act) that complies with the requirements of
the Exchange Act and has been designed by the Company’s principal executive officer and principal
financial officer, or under their supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. Except as disclosed in the
Pricing Prospectus, the Company’s internal control over financial reporting is effective and the
Company is not aware of any material weaknesses in its internal control over financial reporting;

               (xxx) Since the date of the latest audited financial statements included or incorporated by
reference in the Pricing Prospectus, there has been no change in the Company’s internal control
over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting;

               (xxxi) The principal executive officers (or their equivalents) and principal financial
officers (or their equivalents) of the Company have duly made all certifications required by the
Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and any related rules and regulations
promulgated by the Commission, and the statements contained in any such certification are complete
and correct as of the respective dates thereof. The Company has established and maintains and
evaluates “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) under the
Exchange Act); such disclosure controls and procedures are designed to ensure that material
information relating to the Company is made known to the Company’s principal executive officer and
principal financial officer by others within those entities, and such disclosure controls and
procedures are effective to perform the functions for which they were established;

               (xxxii) The Company is in compliance in all material respects with all applicable provisions
of the Sarbanes-Oxley Act and all rules and regulations promulgated thereunder that are then in
effect, is implementing the provisions thereof in accordance thereof, and is actively taking steps
to ensure that it will be in compliance with other applicable provisions of the Sarbanes-Oxley Act
not currently in effect upon the effectiveness of such provisions;

 

 

               (xxxiii) As the time of filing of the Registration Statement, the Company was not, and the
Company on the date of this Agreement is not, an “ineligible issuer” as defined in Rule 405 under
the Act;

               (xxxiv) Without the prior consent of Canaccord Adams Inc., the Company has not made and will
not make any offer relating to the Shares that would constitute a “free writing prospectus” as
defined in Rule 405 under the Act; and any free writing prospectuses, the use of which have been
consented to by the Company and Canaccord Adams Inc., are listed on Schedule III(a) or
III(b) hereto;

               (xxxv) The Company has complied and will comply with the requirements of Rules 164 and 433
under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the
Commission or retention where required and legending;

               (xxxvi) The Company has taken all actions necessary so that any “road show” (as defined in
Rule 433 under the Act) in connection with the offering of the Shares will not be required to be
filed pursuant to the Act and the rules and regulations adopted by the Commission thereunder; and

               (xxxvii) Except as otherwise disclosed in the Pricing Prospectus, the Company and its
subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income
Security Act of 1974, as amended, and the regulations and published interpretations thereunder
(collectively, “ERISA”)) established or maintained by the Company, its subsidiaries or their ERISA
Affiliates (as defined below) are in compliance in all material respects with ERISA. “ERISA
Affiliate” means, with respect to the Company or a subsidiary, any member of any group of
organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as
amended, and the regulations and published interpretations thereunder (the “Code”) of which the
Company or such subsidiary is a member. No “reportable event” (as defined under ERISA) has
occurred or is reasonably expected to occur with respect to any “employee benefit plan” established
or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No “employee
benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA
Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded
benefit liabilities” (as defined under ERISA). Neither the Company, its subsidiaries nor any of
their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV
of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii)
Sections 412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan” established or
maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be
qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by
action or failure to act, which would cause the loss of such qualification.

          (b) Representations, Warranties and Covenants of the Selling Stockholders. Each of the
Selling Stockholders severally represents and warrants to, and agrees with, each of the
Underwriters and the Company that:

               (i) All consents, approvals, authorizations and orders necessary for the execution and
delivery by such Selling Stockholder of this Agreement and the Power of Attorney

 

 

and the Custody Agreement hereinafter referred to, and for the sale and delivery of the Shares
to be sold by such Selling Stockholder hereunder, have been obtained; and such Selling Stockholder
has full right, power and authority to enter into this Agreement, the Power of Attorney and the
Custody Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling
Stockholder hereunder;

               (ii) The sale of the Shares to be sold by such Selling Stockholder hereunder and the
compliance by such Selling Stockholder with all of the provisions of this Agreement, the Power of
Attorney and the Custody Agreement and the consummation of the transactions herein and therein
contemplated will not conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, any statute, indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which such Selling Stockholder is a party or by which
such Selling Stockholder is bound or to which any of the property or assets of such Selling
Stockholder is subject, nor will such action result in any violation of the provisions of the
Certificate of Incorporation or By-laws of such Selling Stockholder if such Selling Stockholder is
a corporation, the Partnership Agreement of such Selling Stockholder if such Selling Stockholder is
a partnership, the Trust Agreement or Declaration of Trust of such Selling Stockholder if such
Selling Stockholder is a trust, the Certificate of Formation or Limited Liability Company Agreement
of such Selling Stockholder if such Selling Stockholder is a limited liability company, or any
statute or any order, rule or regulation of any court or governmental agency or body having
jurisdiction over such Selling Stockholder or the property of such Selling Stockholder;

               (iii) Such Selling Stockholder has, and immediately prior to each Time of Delivery such
Selling Stockholder will have, good and valid title to the Shares to be sold by such Selling
Stockholder hereunder, free and clear of all liens, encumbrances, equities or claims; and, upon
delivery of such Shares and payment therefor pursuant hereto, such Selling Stockholder will
transfer to the several Underwriters, good and valid title to such Shares, free and clear of all
liens, encumbrances, equities or claims;

               (iv) Such Selling Stockholder is not prompted to sell shares of Common Stock by any
information concerning the Company that is not set forth in the Pricing Prospectus;

               (v) During the period beginning from the date hereof and continuing to and including the date
90 days after the date of the Prospectus (the “Lock-Up Period”), such Selling Stockholder will not,
without the prior written consent of Canaccord Adams Inc., (i) sell, offer to sell, contract or
agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree
to dispose of, directly or indirectly, or establish or increase a put equivalent position or
liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange
Act and the rules and regulations of the Commission promulgated thereunder, with respect to any
Common Stock or securities convertible into or exchangeable or exercisable for Common Stock, (ii)
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock, whether any such transaction is to be settled by
delivery of Common Stock or any such securities, in cash or otherwise, or (iii) publicly announce
an intention to effect any transaction specified in clause

 

 

(i) or (ii) above, except the sale of shares by the Selling Stockholder hereunder; provided,
however, that if (a) during the period that begins on the date that is 17 calendar days before the
last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues
an earnings release or material news or a material event relating to the Company occurs, or (b)
prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings
results during the 16-day period beginning on the last day of the Lock-Up Period, then the
restrictions imposed by this clause (v) shall continue to apply until the expiration of the date
that is 18 calendar days after the date of such issuance of the earnings release or the material
news or the material event occurs;

               (vi) Such Selling Stockholder has not taken and will not take, directly or indirectly, any
action which is designed to or which has constituted or which might reasonably be expected to cause
or result in stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Shares;

               (vii) To the extent that any statements or omissions made in the Registration Statement, any
Preliminary Prospectus, the Prospectus or any amendment or supplement thereto are made in reliance
upon and in conformity with written information furnished to the Company by such Selling
Stockholder expressly for use therein, such Registration Statement and Preliminary Prospectus did
not, and the Prospectus and any further amendments or supplements to the Registration Statement and
the Prospectus, when they become effective or are filed with the Commission, as the case may be,
will not, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading;

               (viii) In order to document the Underwriters’ compliance with the reporting and withholding
provisions of the Tax Equity and Fiscal Responsibility Act of 1982 with respect to the transactions
herein contemplated, such Selling Stockholder will deliver to Canaccord Adams Inc. prior to or at
the First Time of Delivery (as hereinafter defined) a properly completed and executed United States
Treasury Department Form W-9 (or other applicable form or statement specified by Treasury
Department regulations in lieu thereof);

               (ix) Certificates in negotiable form representing all of the Shares to be sold by such Selling
Stockholder hereunder have been placed in custody under a Custody Agreement, in the form heretofore
furnished to the Underwriters (the “Custody Agreement”), duly executed and delivered by such
Selling Stockholder to American Stock Transfer & Trust Company, as custodian (the “Custodian”), and such Selling Stockholder has
duly executed and delivered a Power of Attorney, in the form heretofore furnished to Canaccord
Adams Inc. (the “Power of Attorney”), appointing the persons indicated in Schedule II
hereto, and each of them, as such Selling Stockholder’s attorneys-in-fact (the “Attorneys-in-Fact”)
with authority to execute and deliver this Agreement on behalf of such Selling Stockholder, to
determine the purchase price to be paid by the Underwriters to the Selling Stockholders as provided
in Section 3 hereof, to authorize the delivery of the Shares to be sold by such Selling Stockholder
hereunder and otherwise to act on behalf of such Selling Stockholder in connection with the
transactions contemplated by this Agreement and the Custody Agreement;

 

 

               (x) The Shares represented by the certificates held in custody for such Selling Stockholder
under the Custody Agreement are subject to the interests of the Underwriters hereunder; the
arrangements made by such Selling Stockholder for such custody, and the appointment by such Selling
Stockholder of the Attorneys-in-Fact by the Power of Attorney, are irrevocable to the extent
provided thereunder, subject to the terms and conditions of this Agreement; the obligations of the
Selling Stockholders hereunder shall not be terminated by operation of law, whether by the death or
incapacity of any individual Selling Stockholder or, in the case of an estate or trust, by the
death or incapacity of any executor or trustee or the termination of such estate or trust, or in
the case of a partnership or corporation, by the dissolution of such partnership or corporation, or
by the occurrence of any other event; if any individual Selling Stockholder or any such executor or
trustee should die or become incapacitated, or if any such estate or trust should be terminated, or
if any such partnership or corporation should be dissolved, or if any other such event should
occur, before the delivery of the Shares hereunder, certificates representing the Shares shall be
delivered by or on behalf of the Selling Stockholders, subject to and in accordance with, the terms
and conditions of this Agreement and of the Custody Agreements; and actions taken by the
Attorneys-in-Fact pursuant to the Powers of Attorney shall be as valid as if such death,
incapacity, termination, dissolution or other event had not occurred, regardless of whether or not
the Custodian, the Attorneys-in-Fact, or any of them, shall have received notice of such death,
incapacity, termination, dissolution or other event;

               (xi) Such Selling Stockholder is not a member of or an affiliate of or associated with any
member of the NASD; and

               (xii) Neither the Selling Stockholders nor any person acting on behalf of the Selling
Stockholders (other than, if applicable, the Company and the Underwriters) has used or referred or
will use or refer to any “free writing prospectus” as defined in Rule 405 under the Act, relating
to the Shares.

     2. Shares Subject to Sale. On the basis of the representations, warranties and
agreements contained herein, and subject to the terms and conditions of this Agreement:

     (a) The Company and each of the Selling Stockholders agree, severally and not jointly (in
accordance with the allocation set forth in Schedule II hereto), to sell to each of the
Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the
Company and each of the Selling Stockholders, at the First Time of Delivery, at a purchase price
per share of $10.575, the number of Firm Shares (to be adjusted by Canaccord Adams Inc. so as to
eliminate fractional shares) determined in each case by multiplying the aggregate number of Shares
to be sold by the Company and each of the Selling Stockholders as set forth opposite their
respective names in Schedule II hereto by a fraction, the numerator of which is the
aggregate number of Firm Shares to be purchased by such Underwriter as set forth opposite the name
of such Underwriter in Schedule I hereto and the denominator of which is the aggregate
number of Firm Shares to be purchased by all of the Underwriters from the Company and all of the
Selling Stockholders hereunder; and

     (b) In the event and to the extent that the Underwriters shall exercise the election to
purchase Optional Shares as provided below, certain of the Selling Stockholders (as

 

 

and to the extent indicated in Schedule II hereto) agree, severally and not jointly,
to sell to each of the Underwriters, and each of the Underwriters agrees, severally and not
jointly, to purchase from such Selling Stockholders, at the Second Time of Delivery, at the
purchase price per share set forth in clause (a) of this Section 2, that number of Optional Shares
determined by multiplying the number of Optional Shares as to which such election shall have been
exercised (to be adjusted by Canaccord Adams Inc. so as to eliminate fractional shares) by a
fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is
entitled to purchase as set forth opposite the name of such Underwriter in Schedule I
hereto and the denominator of which is the maximum number of Optional Shares that all of the
Underwriters are entitled to purchase hereunder.

     The certain Selling Stockholders, as and to the extent indicated in Schedule II
hereto, hereby grant, severally and not jointly, to the Underwriters the right to purchase at their
election up to 300,000 Optional Shares, at the purchase price per share set forth in clause (a) of
this Section 2, for the sole purpose of covering sales of shares in excess of the number of Firm
Shares. Any such election to purchase Optional Shares shall be made in proportion to the maximum
number of Optional Shares to be sold by each Selling Stockholder as set forth in Schedule
II hereto. Any such election to purchase Optional Shares may be exercised only by written
notice (the “Election Notice”) from Canaccord Adams Inc. to the Selling Stockholders, given within
a period of 30 calendar days after the date of this Agreement and setting forth the aggregate
number of Optional Shares to be purchased and the date on which such Optional Shares are to be
delivered, as determined by Canaccord Adams Inc. but in no event earlier than the First Time of
Delivery or, unless Canaccord Adams Inc. and the Selling Stockholders otherwise agree in writing,
earlier than two or later than ten business days after the date of such notice.

     3. Offering. Upon the authorization by Canaccord Adams Inc. of the release of the Firm
Shares, the several Underwriters propose to offer the Firm Shares for sale upon the terms and
conditions set forth in the Prospectus.

     4. Closing. Certificates in definitive form for the Shares to be purchased by each
Underwriter hereunder, and in such denominations and registered in such names as Canaccord Adams
Inc. may request upon at least forty-eight hours’ prior notice to the Company and the Selling
Stockholders, shall be delivered by or on behalf of the Company and the Selling Stockholders to
Canaccord Adams Inc. for the account of such Underwriter, against payment by such Underwriter or on
its behalf of the purchase price therefor by wire transfer of same day funds to the account
specified by the Company and the Custodian, as their interests may appear, all at the office of
Canaccord Adams Inc., 99 High Street, Boston, Massachusetts 02110. The time and date of such
delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m., Boston time, on
April 11, 2006 or such other time and date as Canaccord Adams Inc. and the Company may agree upon
in writing, and, with respect to the Optional Shares, 9:30 a.m., Boston time, on the date specified
by Canaccord Adams Inc. in the Election Notice, or at such other time and date as Canaccord Adams
Inc. and the Company may agree upon in writing. Such time and date for delivery of the Firm Shares
is herein called the “First Time of Delivery,” such time and date for delivery of the Optional
Shares, if not the First Time of Delivery, is herein called the “Second Time of Delivery,” and each
such time and date for delivery is herein called a “Time of Delivery.” Such certificates will be
made available for checking and packaging at least

 

 

twenty-four hours prior to each Time of Delivery at such location as Canaccord Adams Inc. may
specify. If the Underwriters so elect, delivery of the Shares may be made by credit through full
fast transfer to the accounts at The Depository Trust Company designated by Canaccord Adams Inc.

     5. Covenants of the Company. The Company agrees with each of the Underwriters:

          (a) To prepare the Prospectus in a form approved by the Underwriters and to file such
Prospectus pursuant to Rule 424(b) under the Act not later than the Commission’s close of business
on the second business day following the execution and delivery of this Agreement, or, if
applicable, such earlier time as may be required by the rules and regulations of the Commission
under the Act, to make no further amendment or any supplement to the Registration Statement, the
Pricing Prospectus or Prospectus which shall be reasonably disapproved by Canaccord Adams Inc.
promptly giving reasonable notice thereof; to advise Canaccord Adams Inc., promptly after it
receives notice thereof, of the time when the Registration Statement, or any amendment thereto, has
been filed or becomes effective or any supplement to the Pricing Prospectus or the Prospectus or
any amended Pricing Prospectus or Prospectus has been filed and to furnish Canaccord Adams Inc.
copies thereof; to advise Canaccord Adams Inc., promptly after it receives notice thereof, of the
issuance by the Commission of any stop order or of any order preventing or suspending the use of
any Issuer Free Writing Prospectus, Preliminary Prospectus or Prospectus, of the suspension of the
qualification of the Shares for offering or sale in any jurisdiction, of the initiation or
threatening of any proceeding for any such purpose, or of any request by the Commission for the
amending or supplementing of the Registration Statement, the Pricing Prospectus or Prospectus or
for additional information; and, in the event of the issuance of any stop order or of any order
preventing or suspending the use of any Issuer Free Writing Prospectus, Preliminary Prospectus or
Prospectus or suspending any such qualification, to use promptly its best efforts to obtain its
withdrawal;

          (b) The Company will file promptly all material required to be filed by the Company with the
Commission pursuant to Rule 433(d) under the Act;

          (c) Promptly, from time to time, to take such action as Canaccord Adams Inc. may reasonably
request to qualify the Shares for offering and sale under the securities laws of such jurisdictions
as Canaccord Adams Inc. may request and to comply with such laws so as to permit the continuance of
sales and dealings in such jurisdictions for as long as may be necessary to complete the
distribution of the Shares, provided that in connection therewith the Company shall not be required
to qualify as a foreign corporation or to file a general consent to service of process in any
jurisdiction;

          (d) To furnish the Underwriters with copies of each Issuer Free Writing Prospectus, any
Preliminary Prospectus and the Prospectus in such quantities as the Underwriters may from time to
time reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice
referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine
months after the time of issuance of the Prospectus in connection with the offering or sale of the
Shares and if at such time any events shall have occurred as a result of which the Prospectus as
then amended or supplemented would include an untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements therein, in light

 

 

of the circumstances under which they were made when such Prospectus (or in lieu thereof, the
notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other
reason it shall be necessary during such same period to amend or supplement the Prospectus in order
to comply with the Act, to notify Canaccord Adams Inc. and upon Canaccord Adams Inc.’s request to
prepare and furnish without charge to each Underwriter and to any dealer in securities as many
copies as the Underwriters may from time to time reasonably request of an amended Prospectus or a
supplement to the Prospectus which will correct such statement or omission or effect such
compliance, and in case any Underwriter is required by law to deliver a prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of
the Shares at any time nine months or more after the time of issue of the Prospectus, upon the
Underwriters request but at the expense of such Underwriter, to prepare and deliver to such
Underwriter as many copies as the Underwriters may request of an amended or supplemented Prospectus
complying with Section 10(a)(3) of the Act;

          (e) To make generally available to its security holders as soon as practicable, but in any
event not later than the forty-fifth (45th) day following the end of the full fiscal quarter first
occurring after the first anniversary of the effective date of the Registration Statement (as
defined in Rule 158(c)), an earnings statement of the Company and its subsidiaries (which need not
be audited) complying with Section 11(a) of the Act and the rules and regulations of the Commission
thereunder (including, at the option of the Company, Rule 158);

          (f) During the Lock-Up Period, will not, without the prior written consent of Canaccord Adams
Inc., (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to
purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or
increase a put equivalent position or liquidate or decrease a call equivalent position within the
meaning of Section 16 of the Exchange Act and the rules and regulations of the Commission
promulgated thereunder, with respect to any Common Stock or securities convertible into or
exchangeable or exercisable for Common Stock, (ii) file or cause to be declared effective a
registration statement under the Act relating to the offer and sale of any shares of Common Stock
or securities convertible into or exercisable for Common Stock, (iii) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock, whether any such transaction is to be settled by delivery of Common Stock or any such
securities, in cash or otherwise, or (iv) publicly announce an intention to effect any transaction
specified in clause (i), (ii) or (iii) above, except (A) the registration of Shares and the sale of
Shares to the Underwriters pursuant to this Agreement, (B) the issuance of Common Stock upon the
exercise of options or warrants disclosed as outstanding in the Registration Statement, and (C) the
issuance of employee stock options and distributor warrants not exercisable during the Lock-Up
Period pursuant to stock option or warrant plans described in the Registration Statement; provided,
however, that if (I) during the period that begins on the date that is 17 calendar days before the
last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues
an earnings release or material news or a material event relating to the Company occurs, or (II)
prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings
results during the 16-day period beginning on the last day of the Lock-Up Period, then the
restrictions imposed by this clause (f) shall continue to apply until the expiration of the date
that is 18 calendar days after the date of such issuance of the earnings release or the material
news or the material event occurs;

 

 

          (g) Not to grant options to purchase shares of Common Stock which would become exercisable
during a period beginning from the date hereof and continuing to and including the date 90 days
after the date of the Prospectus;

          (h) To furnish to its stockholders as soon as practicable after the end of each fiscal year an
annual report (including a balance sheet and statements of income, stockholders’ equity and cash
flow of the Company and its consolidated subsidiaries certified by independent public accountants)
and to make available (within the meaning of Rule 158(b) under the Act) as soon as practicable
after the end of each of the first three quarters of each fiscal year (beginning with the fiscal
quarter ending after the effective date of the Registration Statement), consolidated summary
financial information of the Company and its subsidiaries for such quarter in reasonable detail;

          (i) During a period of five years from the effective date of the Registration Statement, to
furnish to the Underwriters upon request copies of all reports or other communications (financial
or other) furnished to stockholders generally, and deliver to the Underwriters as soon as they are
available, copies of any reports and financial statements furnished to or filed with the
Commission, the Nasdaq National Market or any national securities exchange on which any class of
securities of the Company is listed (such financial statements to be on a combined or consolidated
basis to the extent the accounts of the Company and its subsidiaries are combined or consolidated
in reports furnished to its stockholders generally or to the Commission);

          (j) To use the net proceeds acquired by it from the sale of the Shares in the manner specified
in the Pricing Prospectus and the Prospectus under the caption “Use of Proceeds” and in a manner
such that the Company will not become an “investment company” as that term is defined in the
Investment Company Act;

          (k) Not to accelerate the vesting of any option issued under any stock option plan such that
any such option may be exercised within 90 days from the date of the Prospectus;

          (l) To use its best efforts to list for quotation, subject to notice of issuance, the Shares
on the Nasdaq National Market System;

          (m) To file with the Commission such information on Form 10-Q or Form 10-K as may be required
by Rule 463 under the Act;

          (n) To give prompt notice to Canaccord Adams Inc. if at any time following issuance of an
Issuer Free Writing Prospectus any event occurred or occurs as a result of which such Issuer Free
Writing Prospectus would conflict with the information in the Registration Statement, the Pricing
Prospectus or the Prospectus or would include an untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein, in light of the
circumstances then prevailing, not misleading, and, if requested by Canaccord Adams Inc., to
prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus or other
document which will correct such conflict, statement or omission; and

          (o) If the Company elects to rely upon rule 462(b), to file a Rule 462(b) Registration
Statement with the Commission in compliance with Rule 462(b) by 10:00 P.M.

 

 

(Eastern Time), on the date of this Agreement, and at the time of filing to either pay to the
Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable
instructions for the payment of such fee pursuant to Rule 111(b) under the Act.

     6. Expenses. The Company and each of the Selling Stockholders covenant and agree with
one and another and the several Underwriters that (a) the Company will pay or cause to be paid the
following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in
connection with the registration of the Shares under the Act and all other expenses in connection
with the preparation, printing and filing of each Issuer Free Writing Prospectus and the
Registration Statement, any Preliminary Prospectus and the Prospectus and amendments and
supplements thereto, including the work of the Underwriters’ counsel with respect to the drafting
and preparation of the Registration Statement, any Preliminary Prospectus and the Prospectus and
amendments and supplements thereto, and the mailing and delivering of copies thereof to the
Underwriters and dealers; (ii) the cost of reproducing any Agreement Among Underwriters, this
Agreement, the Blue Sky Memorandum and any other documents in connection with the offering,
purchase, sale and delivery of the Shares; (iii) all expenses and filing fees in connection with
the qualification of the Shares for offering and sale under state securities laws as provided in
Section 5(b) hereof and securing any required review by the NASD of the terms of the sale of the
Shares, including the fees and disbursements of counsel for the Underwriters in connection with
such qualification and review and in connection with the Blue Sky Memorandum; (iv) all fees and
expenses in connection with listing the Shares with the Nasdaq National Market; (v) the cost of
preparing stock certificates; (vi) the cost and charges of any transfer agent or registrar; (vii)
all other costs and expenses incident to the performance of the Company’s obligations hereunder
which are not otherwise specifically provided for in this Section and (b) such Selling Stockholder
will pay or cause to be paid all costs and expenses incident to the performance of such Selling
Stockholder’s obligations hereunder which are not otherwise specifically provided for in this
Section, including (i) any fees and expenses of counsel for such Selling Stockholder, (ii) such
Selling Stockholder’s pro rata share of the fees and expenses of the Attorneys-in-Fact and the
Custodian, and (iii) all expenses and taxes incident to the sale and delivery of the Shares to be
sold by such Selling Stockholder to the Underwriters hereunder. In connection with clause (b)(iii)
of the preceding sentence, Canaccord Adams Inc. agrees to pay New York State stock transfer tax,
and the Selling Stockholder agrees to reimburse Canaccord Adams Inc. for associated carrying costs
if such tax payment is not rebated on the day of payment and for any portion of such tax payment
not rebated. It is understood, however, that the Underwriters will pay all of their own costs and
expenses, including the fees and expenses of their counsel, except (y) as provided in this Section,
Section 8 and Section 11 hereof and stock transfer taxes on resale of any of the Shares by them and
(z) for any other expenses aggregating in excess of $250,000 (which will be paid by the Company),
including all advertising, mailing, telephone, road show, travel or other costs incurred by the
Underwriters in connection with the marketing of the public offering contemplated by this
Agreement. The Underwriters currently anticipate expenses pursuant to Section 6(z) not to exceed $400,000.

     7. Conditions of Underwriters’ Obligations. The obligations of the Underwriters
hereunder, as to the Shares to be delivered at each Time of Delivery, shall be subject, in their
discretion, to the condition that all representations and warranties and other statements of the
Company and of the Selling Stockholders herein are, at and as of such Time of Delivery, true and
correct, the condition that the Company and the Selling Stockholders shall have performed

 

 

all of their respective obligations hereunder theretofore to be performed, and the following
additional conditions:

          (a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) within
the applicable time period prescribed for such filing by the rules and regulations under the Act
and in accordance with Section 5(a) hereof; no stop order suspending the effectiveness of the
Registration Statement, any Preliminary Prospectus, the Prospectus or any Issuer Free Writing
Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or
threatened by the Commission; all material required to be filed by the Company pursuant to Rule
433(d) under the Act shall have been filed with the Commission within the applicable time period
prescribed for such filing by Rule 433 under the Act; and all requests for additional information
on the part of the Commission shall have been complied with to Canaccord Adams Inc.’s reasonable
satisfaction;

          (b) O’Melveny & Myers LLP, counsel to the Underwriters, shall have furnished to the
Underwriters such opinion or opinions, dated such Time of Delivery, with respect to this Agreement,
the Registration Statement, the Pricing Disclosure Package, the Prospectus and other related
matters as the Underwriters may reasonably request;

          (c) Vanasco, Genelly & Miller, counsel to the Company, shall have furnished to the
Underwriters their written opinion, dated such Time of Delivery, in form and substance reasonably
satisfactory to the Underwriters, with respect to the matters set forth in Annex I hereto;

          (d) Stephen M. Merrick, Senior Vice President and General Counsel to the Company, shall have
furnished to the Underwriters his written opinion, dated such Time of Delivery, in form and
substance reasonably satisfactory to the Underwriters, with respect to the matters set forth in
Annex II hereto;

          (e) Vanasco, Genelly & Miller, counsel to each of the Selling Stockholders, as indicated in
Schedule II hereto shall have furnished to the Underwriters their written opinion with
respect to each of the Selling Stockholders for whom they are acting as counsel, dated such Time of
Delivery, in form and substance reasonably satisfactory to the Underwriters, with respect to the
matters set forth in Annex III hereto;

          (f) On the date hereof and also at each Time of Delivery, Ernst & Young LLP, shall have
furnished to the Underwriters a letter or letters, dated the respective date of delivery thereof,
in form and substance reasonably satisfactory to the Underwriters, to the effect set forth in
Annex IV hereto;

          (g) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of
the latest audited financial statements included or incorporated by reference in the Pricing
Prospectus any loss or interference with its business from fire, explosion, flood or other
calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and
(ii) since the respective dates as of which information is given in the Pricing Prospectus, there
shall not have been any change in the capital stock (other than issuances of

 

 

Common Stock pursuant to Company stock option and stock purchase plans described in the
Registration Statement and the Pricing Prospectus) or long-term debt of the Company or any material
adverse change in the general affairs, business, assets, management, financial position,
stockholders’ equity or results of operations of the Company and its subsidiaries taken as a whole,
otherwise than as set forth or contemplated in the Pricing Prospectus, the effect of which, in any
such case described in clause (i) or (ii), is in the sole judgment of Canaccord Adams Inc. so
material and adverse as to make it impracticable or inadvisable to proceed with the public offering
or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the
manner contemplated in the Prospectus;

          (h) On or after the date hereof there shall not have occurred any of the following: (i)
additional material governmental restrictions, not in force and effect on the date hereof, shall
have been imposed upon trading in securities generally or minimum or maximum prices shall have been
generally established on the New York Stock Exchange, the Nasdaq National Market, the American
Stock Exchange or in the over-the-counter market by the NASD, or trading in securities generally
shall have been suspended on the New York Stock Exchange, the Nasdaq National Market, the American
Stock Exchange or in the over the counter market by the NASD, or a general banking moratorium shall
have been established by federal or New York authorities, (ii) a suspension or material limitation
in trading in securities generally on the Nasdaq National Market, (iii) a suspension or material
limitation in trading in the Company’s securities on the Nasdaq National Market, (iv) an outbreak
of major hostilities or other national or international calamity or any substantial change in
political, financial or economic conditions shall have occurred or shall have accelerated or
escalated to such an extent, as, in the sole judgment of Canaccord Adams Inc., to affect materially
and adversely the marketability of the Shares or (v) there shall be any action, suit or proceeding
pending or threatened, or there shall have been any development or prospective development
involving particularly the business or properties or securities of the Company or any of its
subsidiaries or the transactions contemplated by this Agreement, which, in the sole judgment of
Canaccord Adams Inc., has materially and adversely affected the Company’s business or earnings and
makes it impracticable or inadvisable to proceed with the public offering or the delivery of the
Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the
Prospectus;

          (i) The Shares to be sold at such Time of Delivery shall have been accepted for quotation,
subject to notice of issuance, on the Nasdaq National Market System;

          (j) Each director and executive officer of the Company, other than a Selling Stockholder,
shall have executed and delivered to the Underwriters agreements in which such person undertakes
that, during the Lock-Up Period, such person will not, without the prior written consent of
Canaccord Adams Inc., (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge,
grant any option to purchase or otherwise dispose of or agree to dispose of, directly or
indirectly, or establish or increase a put equivalent position or liquidate or decrease a call
equivalent position within the meaning of Section 16 of the Exchange Act and the rules and
regulations of the Commission promulgated thereunder, with respect to any Common Stock or
securities convertible into or exchangeable or exercisable for Common Stock, (ii) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock, whether any such transaction is to be settled by delivery of

 

 

Common Stock or any such securities, in cash or otherwise, or (iii) publicly announce an
intention to effect any transaction specified in clause (i) or (ii) above; provided, however, that
if (a) during the period that begins on the date that is 17 calendar days before the last day of
the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an earnings
release or material news or a material event relating to the Company occurs, or (b) prior to the
expiration of the Lock-Up Period, the Company announces that it will release earnings results
during the 16-day period beginning on the last day of the Lock-Up Period, then the restrictions
imposed by this clause (v) shall continue to apply until the expiration of the date that is 18
calendar days after the date of such issuance of the earnings release or the material news or the
material event occurs;

          (k) The Company and the Selling Stockholders shall have furnished or caused to be furnished to
the Underwriters at such Time of Delivery certificates of officers of the Company, in their
capacities as such, and of the Selling Stockholders, respectively, satisfactory to Canaccord Adams
Inc., as to the accuracy of the representations and warranties of the Company and the Selling
Stockholders, respectively, herein at and as of such Time of Delivery, as to the performance by the
Company and the Selling Stockholders, of all of their obligations hereunder to be performed at or
prior to such Time of Delivery, and as to such other matters as the Underwriters may reasonably
request, and the Company shall have furnished or caused to be furnished certificates as to the
matters set forth in subsections (a) and (g) of this Section, and as to such other matters as
Canaccord Adams Inc. may reasonably request.

     8. Indemnification and Contribution.

          (a) The Company and each of the Selling Stockholders, jointly and severally, will indemnify
and hold harmless each Underwriter and each person, if any, who controls such Underwriter against
any losses, claims, damages or liabilities, joint or several, to which such Underwriter or
controlling person may become subject, under the Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue
statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus,
the Registration Statement or the Prospectus, or any amendment or supplement thereto, any Issuer
Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule
433(d) under the Act, any “road show” (as defined in Rule 433 under the Act) not constituting an
Issuer Free Writing Prospectus (a “Non-Prospectus Road Show”) or any “free writing prospectus” (as
defined in Rule 405 under the Act), prepared by or on behalf of any Selling Stockholder or used or
referred to by any Selling Stockholder in connection with the offering of the Shares in violation
of Section 2.(k) hereof (a “Selling Stockholder Free Writing Prospectus”), or arise out of or are
based upon the omission or alleged omission to state therein a material fact, in the case of the
Registration Statement or any amendment thereto, required to be stated therein or necessary to make
the statements therein not misleading and, in the case of any Preliminary Prospectus, the
Prospectus or any supplement thereto, any Issuer Free Writing Prospectus, any “issuer information”
filed or required to be filed pursuant to Rule 433(d) under the Act, a Non-Prospectus Road Show or
a Selling Stockholder Free Writing Prospectus, necessary to make the statements therein, in light
of the circumstances in which they were made, not misleading, and will reimburse each Underwriter
for any legal or other expenses reasonably incurred by such Underwriter in connection with
investigating or defending any such action or claim as such expenses are incurred;
provided, however, that the

 

 

Company and the Selling Stockholders shall not be liable in any such case to the extent that
any such loss, claim, damage or liability arises out of or is based upon an untrue statement or
alleged untrue statement or omission or alleged omission made in any Preliminary Prospectus, the
Registration Statement or the Prospectus or any such amendment or supplement thereto, any Issuer
Free Writing Prospectus or any Non-Prospectus Road Show in reliance upon and in conformity with
written information furnished to the Company by any Underwriter through Canaccord Adams Inc.
expressly for use therein; provided, further, that the aggregate liability of a
Selling Stockholder pursuant to this subsection (a) shall not exceed the product of (i) the number
of Shares sold by such Selling Stockholder, including any Optional Shares, and (ii) the public
offering price of the Shares as set forth in the Pricing Prospectus and the Prospectus.

          (b) Each Underwriter will severally and not jointly indemnify and hold harmless the Company
and each Selling Stockholder against any losses, claims, damages or liabilities to which the
Company or such Selling Stockholder may become subject, under the Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based
upon an untrue statement or alleged untrue statement of a material fact contained in any
Preliminary Prospectus, the Registration Statement or the Prospectus, or any amendment or
supplement thereto, any Issuer Free Writing Prospectus or any Non-Prospectus Road Show, or arise
out of or are based upon the omission or alleged omission to state therein a material fact, in the
case of the Registration Statement or any amendment thereto, required to be stated therein or
necessary to make the statements therein not misleading and, in the case of the Preliminary
Prospectus, the Prospectus or any supplement thereto, any Issuer Free Writing Prospectus or any
Non-Prospectus Road Show, necessary to make the statements therein, in light of the circumstances
in which they were made, not misleading, in each case to the extent, but only to the extent, that
such untrue statement or alleged untrue statement or omission or alleged omission was made in any
Preliminary Prospectus, the Registration Statement or the Prospectus or any such amendment or
supplement thereto, any Issuer Free Writing Prospectus or any Non-Prospectus Road Show in reliance
upon and in conformity with written information furnished to the Company by such Underwriter
through Canaccord Adams Inc. expressly for use therein; and will reimburse the Company and each
Selling Stockholder for any legal or other expenses reasonably incurred by the Company or such
Selling Stockholder in connection with investigating or defending any such action or claim as such
expenses are incurred.

          (c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice
of the commencement of any action, such indemnified party shall, if a claim in respect thereof is
to be made against the indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; provided, however, that the omission so to
notify the indemnifying party shall not relieve it from any liability which it may have to any
indemnified party otherwise than under such subsection. In case any such action shall be brought
against any indemnified party and it shall notify the indemnifying party of the commencement
thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it
shall wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel satisfactory to such indemnified party (who shall not, except with the
consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the
indemnifying party to such indemnified party of its election so to assume the defense thereof, the
indemnifying party shall not be liable to such indemnified party under such subsection for any
legal expenses of other counsel or any other expenses, in each case

 

 

subsequently incurred by such indemnified party, in connection with the defense thereof other
than reasonable costs of investigation. No indemnifying party shall, without the written consent
of the indemnified party, effect the settlement or compromise of, or consent to the entry of any
judgment with respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the indemnified party is an
actual or potential party to such action or claim) unless such settlement, compromise or judgment
(i) includes an unconditional release of the indemnified party from all liability arising out of
such action or claim and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act, by or on behalf of any indemnified party. No indemnifying party
shall be liable for any settlement of any action or claim effected without its written consent,
which consent shall not be unreasonably withheld.

          (d) If the indemnification provided for in this Section 8 is unavailable to or insufficient to
hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses,
claims, damages or liabilities (or actions in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of such losses, claims, damages or liabilities (or actions in respect thereof) in such
proportion as is appropriate to reflect the relative benefits received by the Company and such
Selling Stockholders on the one hand and the Underwriters on the other from the offering of the
Shares. If, however, the allocation provided by the immediately preceding sentence is not
permitted by applicable law or if the indemnified party failed to give the notice required under
subsection (c) above, then each indemnifying party shall contribute to such amount paid or payable
by such indemnified party in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company and the Selling Stockholders on the one hand
and the Underwriters on the other in connection with the statements or omissions which resulted in
such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other
relevant equitable considerations. The relative benefits received by the Company and the Selling
Stockholders on the one hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total net proceeds from the offering (before deducting expenses) received by the
Company and the Selling Stockholders, bear to the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the cover page of the
Pricing Prospectus and the Prospectus. The relative fault shall be determined by reference to,
among other things, whether the untrue or alleged statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company or the
Selling Stockholders on the one hand or the Underwriters on the other and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company, each of the Selling Stockholders and the Underwriters agree that it would
not be just and equitable if contributions pursuant to this subsection (d) were determined by pro
rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any
other method of allocation which does not take account of the equitable considerations referred to
above in this subsection (d). The amount paid or payable by an indemnified party as a result of
the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in
this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by
such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (d), (i) no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the Shares
underwritten by it and distributed to the

 

 

public were offered to the public exceeds the amount of any damages which such Underwriter has
otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or
alleged omission and (ii) no Selling Stockholder shall be required to contribute any amount in
excess of an amount equal to the product of the number of Shares sold by the Selling Stockholder,
including any Optional Shares, and the public offering price of the Shares set forth in the Pricing
Prospectus and the Prospectus. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters’ obligations in this subsection (d)
to contribute are several in proportion to their respective underwriting obligations and not joint.

          (e) The obligations of the Company and the Selling Stockholders under this Section 8 shall be
in addition to any liability which the Company and the respective Selling Stockholders may
otherwise have and shall extend, upon the same terms and conditions, to each person, if any, who
controls any Underwriter within the meaning of the Act; and the obligations of the Underwriter
under this Section 8 shall be in addition to any liability which the respective Underwriters may
otherwise have and shall extend, upon the same terms and conditions, to each officer and director
of the Company and to each person, if any, who controls the Company within the meaning of the Act.

     9. Termination.

          (a) If any Underwriter shall default in its obligation to purchase the Shares which it has
agreed to purchase hereunder at a Time of Delivery, Canaccord Adams Inc. may in its sole discretion
arrange for it or another party or other parties to purchase such Shares on the terms contained
herein. If within thirty-six (36) hours after such default by any Underwriter, Canaccord Adams Inc.
does not arrange for the purchase of such Shares, then the Company and the Selling Stockholders
shall be entitled to a further period of thirty-six (36) hours within which to procure another
party or other parties satisfactory to Canaccord Adams Inc. to purchase such Shares on such terms.
In the event that, within the respective prescribed periods, Canaccord Adams Inc. notifies the
Company and the Selling Stockholders that it has so arranged for the purchase of such Shares, or
the Company and the Selling Stockholders notify Canaccord Adams Inc. that it has so arranged for
the purchase of such Shares, Canaccord Adams Inc. or the Company and the Selling Stockholders shall
have the right to postpone such Time of Delivery for a period of not more than seven (7) days, in
order to effect whatever changes may thereby be made necessary in the Registration Statement or the
Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any
amendments to the Registration Statement or the Prospectus which in Canaccord Adams Inc.’s opinion
may thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any
person substituted under this Section with like effect as if such person had originally been a
party to this Agreement with respect to such Shares.

          (b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by Canaccord Adams Inc. and/or the Company and the Selling Stockholders
as provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased
does not exceed one-tenth of the aggregate number of all the Shares to be purchased at such Time of
Delivery, then the Company and the Selling Stockholders shall

 

 

have the right to require each non-defaulting Underwriter to purchase the number of Shares
which such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to
require each non-defaulting Underwriter to purchase its pro rata share (based on the number of
Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made; but nothing herein
shall relieve a defaulting Underwriter from liability for its default.

          (c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by Canaccord Adams Inc. and the Company and the Selling Stockholders as
provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased
exceeds one-tenth of the aggregate number of all the Shares to be purchased at such Time of
Delivery, or if the Company and the Selling Stockholders shall not exercise the right described in
subsection (b) above to require non-defaulting Underwriters to purchase Shares of a defaulting
Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery,
the obligations of the Underwriters to purchase and of certain Selling Stockholders to sell the
Optional Shares) shall thereupon terminate, without liability on the part of any non-defaulting
Underwriter or the Company or the Selling Stockholders, except for the expenses to be borne by the
Company and the Selling Stockholders and the Underwriters as provided in Section 6 hereof and the
indemnity and contribution agreements in Section 8 hereof, but nothing herein shall relieve a
defaulting Underwriter from liability for its default.

     10. Survival. The respective indemnities, agreements, representations, warranties and
other statements of the Company, the Selling Stockholders and the several Underwriters, as set
forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement,
shall remain in full force and effect, regardless of any investigation (or any statement as to the
results thereof) made by or on behalf of any Underwriter or any controlling person of any
Underwriter, or the Company, or any of the Selling Stockholders or any officer or director or
controlling person of the Company, or any controlling person of any Selling Stockholder and shall
survive delivery of and payment for the Shares.

     11. Expenses of Termination. If this Agreement shall be terminated pursuant to
Section 9 hereof, the Company and the Selling Stockholders shall then have no liability to any
Underwriter except as provided in Section 6 and Section 8 hereof; but, if for any other reason this
Agreement is terminated, or the transactions contemplated hereby shall not have been consummated
due to any of the conditions set forth in Section 7 hereof not having been met, or the Shares are
not delivered by or on behalf of the Company and the Selling Stockholders as provided herein, the
Company will reimburse the Underwriters through Canaccord Adams Inc. for all out-of-pocket expenses
approved in writing by Canaccord Adams Inc., including fees and disbursements of counsel,
reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery
of the Shares not so delivered, but the Company and the Selling Stockholders shall have no further
liability to any Underwriter in respect of the Shares not so delivered except as provided in
Section 6 and Section 8 hereof.

     12. Notice. In all dealings hereunder, Canaccord Adams Inc. shall act on behalf of
each of the Underwriters, and the parties hereto shall be entitled to act and rely upon any
statement, request, notice or agreement on behalf of any Underwriter made or given by

 

 

Canaccord Adams Inc. on behalf of the Underwriters; and in all dealings with any Selling
Stockholder hereunder, Canaccord Adams Inc. and the Underwriters shall be entitled to act and rely
upon any statement, request, notice or agreement on behalf of such Selling Stockholder made or
given by any or all of the Attorneys-in-Fact for such Selling Stockholder.

     All statements, requests, notices and agreements hereunder shall be in writing, and if to the
Underwriters shall be delivered or sent by mail, telex or facsimile transmission to the
Underwriters in care of Canaccord Adams Inc., 99 High Street, 11th Floor, Boston,
Massachusetts 02110, Attention: Equity Capital Markets; if to any Selling Stockholder shall be
delivered or sent by mail, telex or facsimile transmission to counsel for such Selling Stockholder
at its address set forth in Schedule II hereto; and if to the Company shall be delivered or
sent by mail, telex or facsimile transmission to the address of the Company set forth in the
Registration Statement, Attention: President; provided, however, that any notice to
an Underwriter pursuant to Section 8(c) hereof shall be delivered or sent by mail, telex or
facsimile transmission to such Underwriter at its address set forth in its Underwriter’s
Questionnaire or telex constituting such Questionnaire, which address will be supplied to the
Company by Canaccord Adams Inc. on request. Any such statements, requests, notices or agreements
shall take effect upon receipt thereof.

     13. Information Provided by the Underwriters. The Company, the Selling Stockholders
and the Underwriters acknowledge that, for purposes of this Agreement, the statements set forth in
paragraphs one and six under the heading “Underwriting” in the Pricing Prospectus and the
Prospectus constitute the only information furnished in writing to the Company by any Underwriter
through Canaccord Adams Inc. expressly for use in the Registration Statement, any Preliminary
Prospectus or the Prospectus. In addition, the Company, the Selling Stockholders and the
Underwriters acknowledge that, for purposes of this Agreement, no information has been furnished in
writing to the Company by any Underwriter through Canaccord Adams Inc. expressly for use in any
Issuer Free Writing Prospectus or Non-Prospectus Road Show.

     14. Miscellaneous.

          (a) This Agreement shall be binding upon, and inure solely to the benefit of, the
Underwriters, the Selling Stockholders and the Company and, to the extent provided in Sections 8
and 10 hereof, the officers and directors of the Company and each person who controls the Company,
any Selling Stockholder or any Underwriter, and their respective heirs, executors, administrators,
successors and assigns, and no other person shall acquire or have any right under or by virtue of
this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor
or assign by reason merely of such purchase.

          (b) Time shall be of the essence of this Agreement. As used herein, the term “business day”
shall mean any day when the Commission’s office in Washington, D.C. is open for business.

          (c) This Agreement shall be governed by and construed in accordance with the laws of The
Commonwealth of Massachusetts.

 

 

          (d) This Agreement may be executed by any one or more of the parties hereto in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same instrument.

          (e) The Company, the Selling Stockholders and the Underwriters acknowledge and agree that (i)
the purchase and sale of the Shares pursuant to this Agreement is an arm’s-length commercial
transaction between the Company and the Selling Stockholders, on the one hand, and the several
Underwriters, on the other, (ii) in connection therewith and with the process leading to such
transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the
Company or the Selling Stockholders, (iii) no Underwriter has assumed an advisory or fiduciary
responsibility in favor of the Company or the Selling Stockholders with respect to the offering
contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has
advised or is currently advising the Company or any Selling Stockholder on other matters) or any
other obligation to the Company or any Selling Stockholder except the obligations expressly set
forth in this Agreement and (iv) the Company and the Selling Stockholders have consulted their own
legal advisors to the extent they deemed appropriate. The Company and the Selling Stockholders
agree that they will not claim that the Underwriters, or any of them, has rendered advisory
services of any nature or respect, or owes a fiduciary or similar duty to the Company or the
Selling Stockholders, in connection with such transaction or the process leading thereto.

 

 

     If the foregoing is in accordance with your understanding, please sign and return to us six
counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters,
this letter and such acceptance hereof shall constitute a binding agreement among each of the
Underwriters and the Company, and the Selling Stockholders. It is understood that your acceptance
of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in an
Agreement among Underwriters, the form of which shall be submitted to the Company and the Selling
Stockholders for examination, upon request, but without warranty on your part as to the authority
of the signors thereof.

     Any person executing and delivering this Agreement as Attorney in Fact for a Selling
Stockholder represents by so doing that he has been duly appointed as Attorney in Fact by such
Selling Stockholder pursuant to a validly existing and binding Power-of-Attorney which authorizes
such Attorney in Fact to take such action.

	 	 	 	 	 
	 	 	Very truly yours,
	 
	 	 	 	 
	 	 	RELÌV INTERNATIONAL, INC.
	 
	 	 	 	 
	 

	 	By:	 	/s/ Steven D. Albright
	 

	 	 	 	 
	 

	 	 	 	Name: Steven D. Albright
	 

	 	 	 	Title: Vice President and Chief
Financial Officer
	 
	 	 	 	 
	 	 	ROBERT L. MONTGOMERY, as a Selling Stockholder
	 
	 	 	 	 
	 

	 	By:	 	/s/ Steven D. Albright
	 

	 	 	 	 
	 

	 	 	 	Steven D. Albright
	 

	 	 	 	Attorney-in-Fact
	 
	 	 	 	 
	 	 	CARL W. HASTINGS, as a Selling Stockholder
	 
	 	 	 	 
	 

	 	By:	 	/s/ Steven D. Albright
	 

	 	 	 	 
	 

	 	 	 	Steven D. Albright
	 

	 	 	 	Attorney-in-Fact

 

 

	 	 	 	 	 
	 	 	STEPHEN M. MERRICK, as a Selling Stockholder
	 
	 	 	 	 
	 

	 	By:	 	/s/ Steven D. Albright
	 

	 	 	 	 
	 

	 	 	 	Steven D. Albright
	 

	 	 	 	Attorney-in-Fact
	 
	 	 	 	 
	 	 	DONALD L. MCCAIN, as a Selling Stockholder
	 
	 	 	 	 
	 

	 	By:	 	/s/ Steven D. Albright
	 

	 	 	 	 
	 

	 	 	 	Steven D. Albright
	 

	 	 	 	Attorney-in-Fact

 

 

Accepted as of the date hereof at Boston, Massachusetts

CANACCORD ADAMS INC.,

AVONDALE PARTNERS, LLC

THE SEIDLER COMPANIES INCORPORATED

	 	 	 	 	 
	By:

	 	/s/ Joseph W. Hammer	 
	 

	 	 	 
	 

	 	(Canaccord Adams Inc. on	 
	 

	 	behalf of each of the Underwriters)	 	 
	 

	 	Name:	Joseph W. Hammer	 
	 

	 	Title:	Managing Director	 

 

 

SCHEDULE I

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Number of	 
	 	 	 	 	 	 	Optional Shares	 
	 	 	Total Number	 	 	to be Purchased	 
	 	 	of Firm Shares	 	 	if Maximum	 
	 	 	to be Purchased	 	 	Option Exercised	 
	Canaccord Adams Inc.
	 	 	800,000	 	 	 	120,000	 
	Avondale Partners, LLC
	 	 	600,000	 	 	 	90,000	 
	The Seidler Companies Incorporated
	 	 	600,000	 	 	 	90,000	 
	TOTAL 
	 	 	2,000,000	 	 	 	300,000	 

 

 

SCHEDULE II

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Number of	 
	 	 	 	 	 	 	Optional Shares	 
	 	 	Total Number	 	 	to be Sold	 
	 	 	of Firm Shares	 	 	if Maximum	 
	 	 	to be Sold	 	 	Option Exercised	 
	The Company
	 	 	1,200,000	 	 	 	-0-	 
	The Selling Stockholders
	 	 	 	 	 	 	 	 
	Robert L. Montgomery (1) 
	 	 	400,000	 	 	 	-0-	 
	Carl W. Hastings (1) 
	 	 	160,000	 	 	 	150,000	 
	Stephen M. Merrick (1) 
	 	 	160,000	 	 	 	150,000	 
	Donald L. McCain (1) 
	 	 	80,000	 	 	 	-0-	 
	 
	 	 	 	 	 	 
	 
	TOTAL 
	 	 	2,000,000	 	 	 	300,000	 
	 
	 	 	 	 	 	 

 

			
	(1)	 	This Selling Stockholder is represented by Vanasco, Genelly & Miller and has appointed
Robert L. Montgomery and Steven D. Albright, as the Attorneys-in-Fact for such Selling Stockholder.

 

 

SCHEDULE III(a)

None.

 

 

SCHEDULE III(b)

Underwriter
Pricing Wire, dated April 5, 2006

 

 

ANNEX I

          Form of Opinion of Vanasco, Genelly & Miller, as Counsel to the Company

     1. The Company is a corporation duly incorporated, validly existing and in good standing with
the Secretary of State of the State of Delaware with corporate power and authority to own, lease
and operate its properties and conduct its business as described in the Prospectus. The Company is
duly qualified to do business and is in good standing in each jurisdiction within the United States
in which it owns or leases real property or maintains an office.

     2. The
authorized capitalization of the Company as of December 31, 2005 is as set forth under
the caption “Capitalization” in the Prospectus. All of the issued and outstanding shares of
capital stock have been duly authorized and validly issued and are fully paid and nonassessable and
have not been issued in violation of any statutory preemptive right, any participation,
subscription or similar right in the Company’s organizational documents or, to our knowledge, any
other similar contractual right. The Shares have been duly authorized and, when issued and
delivered in accordance with the Underwriting Agreement, will be validly issued, fully paid and
nonassessable and will conform in all material respects to the description of the capital stock
contained in the Prospectus.

     3. Each domestic subsidiary of the Company is a corporation duly incorporated, validly
existing and in good standing under the laws of the jurisdiction of its organization. All of the
issued and outstanding shares of capital stock of each such subsidiary (i) have been duly
authorized and validly issued and are fully paid and nonassessable and (ii) except as disclosed in
the Prospectus, are owned of record and, to our knowledge, beneficially by the Company or another
subsidiary of the Company, free and clear of all liens, encumbrances, equities or claims and, to
the best of our knowledge, have been issued in compliance with Federal and state securities laws.
Each domestic subsidiary of the Company is duly qualified to do business and is in good standing in
each jurisdiction within the United States in which it owns or leases real property or maintains an
office. As to the opinions in the second sentence of paragraph 2 above and this entire paragraph
3, we have relied upon opinions of local counsel and in respect of matters of fact upon
certificates of officers of the Company and its subsidiaries. We believe that both you and we are
justified in relying upon such opinions and certificates.

     4. The Company has the corporate power and authority to enter into the Underwriting Agreement
and perform its obligations thereunder and the Underwriting Agreement has been duly authorized,
executed and delivered by the Company.

     5. The issuance and sale by the Company of the Shares and the performance by the Company of
its obligations under the Underwriting Agreement does not and will not (i) violate the certificate
of incorporation or by-laws of the Company, (ii) breach or result in a default under any agreement,
indenture or other instrument filed as an exhibit to the Registration Statement or any document
incorporated by reference into the Registration Statement to which the Company is a party or by
which it is bound, or to which any of its properties is subject, or (iii) violate any law, rule or
administrative regulation or any order or decree known to us of any court or any governmental
agency or body having jurisdiction over the Company or any of its properties,

Annex I-1

 

except that we express no opinion as to state securities or “Blue Sky” laws or as to
compliance with the anti-fraud provisions of federal and state securities laws.

     6. No consent, approval, authorization, order, registration or qualification of or with any
court or governmental agency or body is required for the issuance and sale of the Shares by the
Company or the consummation by the Company of the transactions contemplated by the Underwriting
Agreement, except the registration under the Act of the Shares.

     7. The Company is not, and after receipt of payment for the Shares will not be, an “investment
company” as such term is defined in the Investment Company Act of 1940, as amended.

     8. The Shares have been authorized for inclusion on the Nasdaq National Market System, subject
to notice of issuance.

     9. To our knowledge and other than as set forth in the Prospectus, there are no legal or
governmental proceedings pending to which the Company or any of its subsidiaries is a party or of
which any property of the Company or any of its subsidiaries is the subject which, if determined
adversely to the Company or any of its subsidiaries, would individually or in the aggregate have a
material adverse effect on the current or future consolidated financial position, stockholders’
equity or results of operations of the Company and its subsidiaries; and, to our knowledge, no such
proceedings are threatened or contemplated by governmental authorities or threatened by others.

     10. Each of the Registration Statement and the Rule 462(b) Registration Statement, if any, has
been declared effective by the Commission under the Securities Act. To the best of our knowledge,
no stop order suspending the effectiveness of the Registration Statement or the Rule 462(b)
Registration Statement, if any, has been issued under the Securities Act and no proceedings for
such purpose have been instituted or are pending or are contemplated or threatened by the
Commission. Any required filing of the Prospectus and any supplement thereto pursuant to Rule
424(b) under the Securities Act has been made in the manner and within the time period required by
such Rule 424(b).

     11. The Registration Statement, including any Rule 462(b) Registration Statement, the
Prospectus, and each amendment or supplement to the Registration Statement and the Prospectus, as
of their respective effective or issue dates (other than the financial statements and supporting
schedules included therein or in exhibits to or excluded from the Registration Statement, as to
which no opinion need be rendered) comply as to form in all material respect with the applicable
requirements of the Act.

     12. The statements under the captions “Underwriting” in the Prospectus, to the extent they
constitute matters of law or legal conclusions, have been reviewed by us and are fair in all
material respects of such matters and conclusions; and the statements set forth under the headings
“Business-Intellectual Property,” “Business-Regulation” and “Description of Capital Stock” in the
Prospectus, insofar as such statements purport to summarize legal matters, documents or
proceedings, provide a fair summary of such legal matters, documents and proceedings;

Annex I-2

 

     13. The documents incorporated by reference in the Prospectus (other than the financial
statements and related schedules therein, as to which we express no opinion), when they were filed
with the Commission, complied as to form in all material respects with the requirements of the
Exchange Act and the rules and regulations of the Commission thereunder.

     As counsel to the Company with respect to the preparation by the Company of the Registration
Statement, the Pricing Prospectus and the Prospectus [and each Issuer Free Writing Prospectus], we
have participated in discussions with your representatives and those of the Company and its
independent accountants in which the business and affairs of the Company and the contents of the
Registration Statement, the Pricing Prospectus and Prospectus [and each Issuer Free Writing
Prospectus] were discussed. On the basis of information that we have gained in connection with the
Company’s preparation of the Registration Statement, the Pricing Prospectus and Prospectus [and
each Issuer Free Writing Prospectus] and our participation in the discussions referred to above,
based on such information and participation, nothing came to our attention that caused us to
believe that (i) the Registration Statement as of its effective date contained an untrue statement
of material fact or omitted to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, (ii) that the Prospectus as of its date contained or as
of such Time of Delivery contains any untrue statement of a material fact or omitted or omits to
state any material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (iii) the Pricing Prospectus, as of its date, the
Applicable Time and at such Time of Delivery, in each case together with the Issuer Free Writing
Prospectuses and with the information relating to the public offering price of the Shares as set
forth on the cover page of the Prospectus, includes or included an untrue statement of a material
fact or omitted to state a material fact necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading or (iv) it is necessary to amend the
Registration Statement. We express no statement, however, as to the financial statements,
including the notes and schedules thereto, or any other financial or accounting information set
forth or referred to in the Registration Statement, the Pricing Prospectus and the Prospectus [and
any Issuer Free Writing Prospectus].

     The determinations involved in our review are such that we do not assume any responsibility for the
accuracy, completeness or fairness of the statements made or the information contained in the
Registration Statement, the Pricing Prospectus and the Prospectus except for those made under the
captions “Business-Intellectual Property,” “Business-Regulation,” “Description of Capital Stock”
and “Underwriting,” which accurately summarize in all material respects the provisions of the laws
and documents referred to therein.

Annex I-3

 

ANNEX II

Form of Opinion of Stephen M. Merrick, Senior Vice President and General Counsel

to the Company

     To my knowledge and other than as set forth in the Prospectus, there are no legal or
governmental proceedings pending to which the Company or any of its subsidiaries is a party or of
which any property of the Company or any of its subsidiaries is the subject which, if determined
adversely to the Company or any of its subsidiaries, would individually or in the aggregate have a
material adverse effect on the current or future consolidated financial position, stockholders’
equity or results of operations of the Company and its subsidiaries; and, to my knowledge, no such
proceedings are threatened or contemplated by governmental authorities or threatened by others.

     As General Counsel to the Company in the course of the preparation by the Company of the
Registration Statement, the Pricing Prospectus and the Prospectus [and each Issuer Free Writing
Prospectus], I have participated in discussions with your representatives and those of the Company
and its independent accountants in which the business and affairs of the Company and the contents
of the Registration Statement, the Pricing Prospectus and Prospectus [and each Issuer Free Writing
Prospectus] were discussed. On the basis of information that I have gained in the course of my
representation of the Company in connection with its preparation of the Registration Statement, the
Pricing Prospectus and Prospectus [and each Issuer Free Writing Prospectus] and my participation in
the discussions referred to above, based on such information and participation, nothing came to my
attention that caused me to believe that (i) the Registration Statement as of its effective date
contained an untrue statement of material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, (ii) that the Prospectus
as of its date contained or as of such Time of Delivery contains any untrue statement of a material
fact or omitted or omits to state any material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading, (iii) the Pricing
Prospectus, as of its date, the Applicable Time and at such Time of Delivery, in each case together
with the Issuer Free Writing Prospectuses and with the information relating to the public offering
price of the Shares as set forth on the cover page of the Prospectus, includes or included an
untrue statement of a material fact or omitted to state a material fact necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading or
(iv) it is necessary to amend the Registration Statement. I express no statement, however, as to
the financial statements, including the notes and schedules thereto, or any other financial or
accounting information set forth or referred to in the Registration Statement, the Pricing
Prospectus and the Prospectus [and any Issuer Free Writing Prospectus].

     The determinations involved in my review are such that I do not assume any responsibility for
the accuracy, completeness or fairness of the statements made or the information contained in the
Registration Statement, the Pricing Prospectus and the Prospectus.

Annex II-1

 

ANNEX III

Form of Opinion of Vanasco, Genelly & Miller, as Counsel to the Selling Stockholders

     1. A Power-of-Attorney and a Custody Agreement have been duly executed and delivered by such
Selling Stockholder and constitute valid and binding agreements of such Selling Stockholder in
accordance with their terms;

     2. The Underwriting Agreement has been duly executed and delivered by or on behalf of such
Selling Stockholder; and the sale of the Shares to be sold by such Selling Stockholder hereunder
and the compliance by such Selling Stockholder with all of the provisions of the Underwriting
Agreement, the Power-of-Attorney and the Custody Agreement and the consummation of the transactions
herein and therein contemplated will not conflict with or result in a breach or violation of any
terms or provisions of, or constitute a default under, any statute, indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument known to us to which such Selling
Stockholder is a party or by which such Selling Stockholder is bound or to which any of the
property or assets of such Selling Stockholder is subject, nor will such action result in any
violation of the provisions of the Certificate of Incorporation or By-laws of such Selling
Stockholder if such Selling Stockholder is a corporation, the Partnership Agreement of such Selling
Stockholder if such Selling Stockholder is a partnership, the Trust Agreement or Declaration of
Trust of such Selling Stockholder if such Selling Stockholder is a trust, the Certificate of
Formation or Limited Liability Company Agreement of such Selling Stockholder if such Selling
Stockholder is a limited liability company, or any order, rule or regulation known to us of any
court or governmental agency or body having jurisdiction over such Selling Stockholder or the
property of such Selling Stockholder;

     3. No consent, approval, authorization or order of any court or governmental agency or body is
required for the consummation of the transactions contemplated by this Agreement in connection with
the Shares to be sold by such Selling Stockholder hereunder, except registration of the Shares
under the Act, or an exemption therefrom, and such as may be required under state securities or
Blue Sky laws in connection with the purchase and distribution of such Shares by the Underwriters;

     4. Immediately prior to such Time of Delivery, such Selling Stockholder had good and valid
title to the Shares to be sold at such Time of Delivery by such Selling Stockholder under this
Agreement, free and clear of all liens, encumbrances, equities or claims, and full right, power and
authority to sell, assign, transfer and deliver the Shares to be sold by such Selling Stockholder
hereunder; and

     5. Good
and valid title to such Shares, free and clear of all liens,
encumbrances, equities or claims, has been transferred to each of the
several Underwriters who have purchased such Shares in good faith and without notice of any such lien, encumbrance, equity or claim or any other adverse claim within the meaning of the Uniform Commercial Code.

Annex III-1

 

ANNEX IV

     Pursuant to Section 7(f) of the Underwriting Agreement, Ernst & Young LLP shall furnish
letters to the Underwriters to the effect that:

               (i) They are independent certified public accountants with respect to the Company and its
subsidiaries within the meaning of the Act and the applicable published rules and regulations
thereunder;

               (ii) In their opinion, the financial statements and any supplementary financial information
and schedules (and, if applicable, pro forma financial information) examined by them and included
or incorporated by reference in the Registration Statement or the Prospectus comply as to form in
all material respects with the applicable accounting requirements of the Act or the Exchange Act,
if applicable, and the related published rules and regulations thereunder; and, if applicable, they
have made a review in accordance with standards established by the American Institute of Certified
Public Accountants of the consolidated interim financial statements, selected financial data, pro
forma financial information and/or condensed financial statements derived from audited financial
statements of the Company for the periods specified in such letter, as indicated in their reports
thereon, copies of which have been separately furnished to the Underwriters;

               (iii) They have made a review in accordance with standards established by the American
Institute of Certified Public Accountants of the unaudited condensed consolidated statements of
income, consolidated balance sheets and consolidated statements of cash flows included in the
Prospectus and/or included in the Company’s Quarterly Reports on Form 10-Q incorporated by
reference into the Prospectus as indicated in their reports thereon, copies of which have been
separately furnished to the Underwriters; and on the basis of specified procedures including
inquiries of officials of the Company who have responsibility for financial and accounting matters
regarding whether the unaudited condensed consolidated financial statements referred to in
paragraph (v)(A)(i) below comply as to form in all material respects with the applicable accounting
requirements of the Act and the Exchange Act and the related published rules and regulations,
nothing came to their attention that caused them to believe that the unaudited condensed
consolidated financial statements do not comply as to form in all material respects with the
applicable accounting requirements of the Act and the Exchange Act and the related published rules
and regulations;

               (iv) The unaudited selected financial information with respect to the consolidated results of
operations and financial position of the Company for the five most recent fiscal years included in
the Prospectus and included or incorporated by reference in Item 6 of the Company’s Annual Report
on Form 10-K for the most recent fiscal year, agrees with the corresponding amounts (after
restatement where applicable) in the audited consolidated financial statements for such five fiscal
years which were included or incorporated by reference in the Company’s Annual Report on Form 10-K
for such fiscal years;

               (v) On the basis of limited procedures, not constituting an examination in accordance with
generally accepted auditing standards, consisting of a reading of the unaudited financial
statements and other information referred to below, a reading of the latest

Annex IV-1

 

available interim financial statements of the Company and its subsidiaries, inspection of the
minute books of the Company and its subsidiaries since the date of the latest audited financial
statements included or incorporated by reference in the Prospectus, inquiries of officials of the
Company and its subsidiaries responsible for financial and accounting matters and such other
inquiries and procedures as may be specified in such letter, nothing came to their attention that
caused them to believe that:

(A) (i) the unaudited condensed consolidated statements of income, consolidated
balance sheets and consolidated statements of cash flows included in the Prospectus
and/or included or incorporated by reference in the Company’s Quarterly Reports on
Form 10-Q incorporated by reference in the Prospectus do not comply as to form in
all material respects with the applicable accounting requirements of the Act and the
Exchange Act as it applies to Form 10-Q and the related published rules and
regulations, or (ii) any material modifications should be made to the unaudited
condensed consolidated statements of income, consolidated balance sheets and
consolidated statements of cash flows included in the Prospectus or included in the
Company’s Quarterly Reports on Form 10-Q incorporated by reference in the
Prospectus, for them to be in conformity with generally accepted accounting
principles;

(B) any other unaudited income statement data and balance sheet items included in
the Prospectus do not agree with the corresponding items in the unaudited
consolidated financial statements from which such data and items were derived, and
any such unaudited data and items were not determined on a basis substantially
consistent with the basis for the corresponding amounts in the audited consolidated
financial statements included in the Prospectus or incorporated by reference to the
Company’s Annual Report on Form 10-K for the most recent fiscal year;

(C) the unaudited financial statements which were not included in the Prospectus but
from which were derived any unaudited condensed financial statements referred to in
clause (A) and any unaudited income statement data and balance sheet items included
in the Prospectus and referred to in clause (B) were not determined on a basis
substantially consistent with the basis for the audited consolidated financial
statements included in the Prospectus or incorporated by reference to the Company’s
Annual Report on Form 10-K for the most recent fiscal year;

(D) any unaudited pro forma consolidated condensed financial statements included or
incorporated by reference in the Prospectus do not comply as to form in all material
respects with the applicable accounting requirements of the Act and the published
rules and regulations thereunder or the pro forma adjustments have not been properly
applied to the historical amounts in the compilation of those statements;

(E) as of a specified date not more than five days prior to the date of such letter,
there have been any changes in the consolidated capital stock (other than

Annex IV-2

 

issuances of capital stock upon exercise of options and stock appreciation rights,
upon earn-outs of performance shares and upon conversions of convertible securities,
in each case which were outstanding on the date of the latest financial statements
included or incorporated by reference in the Prospectus) or any increase in the
combined long-term debt of the Company and its subsidiaries, or any decreases in
combined net current assets or net assets or other items specified by the
Underwriters, or any increases in any items specified by the Underwriters, in each
case as compared with amounts shown in the latest balance sheet included or
incorporated by reference in the Prospectus, except in each case for changes,
increases or decreases which the Prospectus discloses have occurred or may occur or
which are described in such letter; and

(F) for the period from the date of the latest financial statements included or
incorporated by reference in the Prospectus to the specified date referred to in
clause (E) there were any decreases in consolidated net revenues or operating profit
or the total or per share amounts of consolidated net income or other items
specified by the Underwriters, or any increases in any items specified by the
Underwriters, in each case as compared with the comparable period of the preceding
year and with any other period of corresponding length specified by the
Underwriters, except in each case for decreases or increases which the Prospectus
discloses have occurred or may occur or which are described in such letter; and

               (vi) In addition to the examination referred to in their report(s) included or incorporated by
reference in the Prospectus and the limited procedures, inspection of minute books, inquiries and
other procedures referred to in paragraphs (iii) and (v) above, they have carried out certain
specified procedures, not constituting an examination in accordance with generally accepted
auditing standards, with respect to certain amounts, percentages and financial information
specified by the Underwriters which are derived from the general accounting records of the Company
and its subsidiaries, which appear in the Prospectus, or in Part II of, or in exhibits and
schedules to, the Registration Statement specified by the Underwriters, and have compared certain
of such amounts, percentages and financial information with the accounting records of the Company
and its subsidiaries and have found them to be in agreement.

Annex IV-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]